LIST OF MEETING ABSTRACTS
Click the abstract for more detail or request a copy of posters or oral presentations (Powerpoint, PPT format).

Date	Publication
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Moltó, J.; Santos, J.; Pérez-Alvarez, N.; Cedeño, S.; Miranda, C.; Khoo, S.; Else, L.; Llibre, JM.; Valle, M.; Clotet, B.   Inhibitory quotient as a predictor of virological response to darunavir-based salvage regimens.
2008	Ninth International Congress on Drug Therapy in HIV Infection . 09th-13th November 2008; Glasgow, UK.
Rodriguez-Arrondo, F.; Aguirrebengoa, K.; Portu, J.; Muñoz, J.; Garcia, MA.; Goikoetxea, JA.; Martinez, E.; Iribarren, JA.; Perez, N.; Alcarez, C.; Clotet, B.   Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies.
2008	Ninth International Congress on Drug Therapy in HIV Infection 2008. 09th-13th November 2008; Glasgow, UK.
Reekie, J.; Mocroft, A.; Ledergerber, B.; Beniowski, M.; Clotet, B.; Van Lunzen, J.; Chiesi, A.; Pradier, C.; Machala, L.; Lundgren, JD.   Patterns of prior viral suppression on cART as predictors of future risk of viral rebound.
2008	XVII International AIDS Conference. 3rd-8th August 2008, Mexico City. [Abstract TUPE0110]
Martínez, E.; Arranz, JA.; Podzamczer, D.; Loncá, M.; Sanz, J.; Barragán, P.; Ribera, E.; Knobel, H.; Roca, V.; Gutiérrez, F.; Blanco, JL.; Mallolas, J.; Llibre, JM.; Clotet, B.; Dalmau, D.; Segura, F.; Arribas, JR.; Cosín, J.; Barrufet, P.; Pich, J.; Cruceta, A.; Arnaiz, A.; Miró, JM.; Pérez, I.; Gatell, JM.; for the BICOMBO Study Team.  Efficacy and safety of nevirapine (vs. efavirenz) in combination with fixed-dose once-daily abacavir/lamivudine and tenofovir/emtricitabine: a subanalysis of the BICOMBO study.
2008	10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 06th-08th November 2008; London, UK.
Garrabou, G.; Negredo, E.; Moren, C.; Romeu, J.; Rodriguez-Santiago, B.; Nicolàs, N.; Miró, O.; Cardellach, F.; Puig, J.; Pérez-Álvarez, N.; López-Blánquez, R.; Ruiz, L.; Bellido, R.; Miranda, C.; Clotet, B.   Effects of a 144-week-long CD4-guided HIV treatment interruption on mitochondria.
2008	15th. Conference on Retroviruses and Opportunistic Infections. , 3rd-6th February 2008; Boston, USA.
Cabrera, C.; Marfil, S.; Garcia, E.; Ruiz, L.; Bofill, M.; Clotet, B.; Blanco, J.  Impaired replication conferred by the N43D Gp41 mutation could be restored by changes in the Gp120 protein.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Franco, S.; Clotet, B.; Martinez, M.  A Novel HCV NS3/4ª protease assay using a bacteriophage lambda-based genetic screen.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Izquierdo-Useros, N.; Erkizia, I.; Blanco, J.; Wiley, R.; Newton, E.; Archer, J.; Hatch, S.; Clotet, B.; Martinez-Picado, J.; Gummuluru, R.  Characterization of a novel mechanism of an envelope glycoprotein-independent HIV-1 capture and transmission mediated by mature dendritic cells.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Johnson, M.; Campbell, T.; Clotet, B.; Katlama, C.; Lazzarin, A.; Towner, W.; Peeters, M.; Vingerhoets, J.; Bollen, S.; De Smedt, G. on the behalf of the DUET-2 Study Group.   DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 infected patients.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Llibre, JM.; Santos, JR.; Puig, T.; Blanco, A.; Paredes, R.; Mothe, B.; Clotet, B.   Prevalence of mutations with effect on virological response to etravirine in routine clinical samples.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Massanella, M.; Puigdomenech, I.; Fernandez, M.; Bofill, M.; Clotet, B.; Blanco, J.   Differential effect of broadly neutralizing anti-HIV-1 antibodies on the formation of virological synapses.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Perez-Alvarez, N.; Llibre, JM.; Clotet, B.; Conference call spanish group.  Usefulness of a Dendogram Plot Technique in Clustering Homogeneous Subgroups of Multi-treated HIV-1 Patients in Accordance with their Mutational Pattern.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Perez-Alvarez, N.; Llibre, JM.; Clotet, B.; Conference call spanish group.   Usefulness of a Dendogram Plot Technique in Clustering Homogeneous Subgroups of Multi-treated HIV-1 Patients in Accordance with their Mutational Pattern.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Podzamczer, D.; Olmo, M.; Sanz, J.; Bois, V.; Clotet, B.; Knobel, H.; Leibenger, G.; Domingo, P.; Pineda, J.; Vilades, C.; NODy study group.   Low hepatoxicity in patients randomized to switching to nevirapine once daily vs continuing with nevirapine twice daily.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Podzamczer, D.; Ferrer, E.; Martinez, E.; del Rio, L.; Ruiz, I.; Rosales, J.; Ribera, E.; Barrufet, P.; Llibre, JM.; Aranda, M.; and the ABCDE Study Team.   How Much Fat Loss is Needed for Lipoatrophy to Become Clinically Evident?.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Puigdomenech, I.; Massanella, M.; Izquierdo-Useros, N.; Curriu, M.; Ruiz-Hernandez, R.; Bofill, M.; Martinez-Picado, J.; Juan, M.; Clotet, B.; Blanco, J.   Cell-to-cell HIV transmission targets CD45RO+ CD4 T cells through LFA-1-dependent and independent mechanisms.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Tor, J.; Tural, C.; Muga, R.; Ojanguren, I.; Barluenga, E.; Sanvisens, A.; Martinez, E.; Rey-Joly, C.; Clotet, B.   rospective validation of simple biological markers in assessing liver fibrosis in HIV/HCV/co-infected patients.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Cozzi-Lepri, A.; Cunnington, M.; Lazzarin, A.; Clotet, B.; Knysz, B.; Gargalianos, P.; Katlama, C.; Karlsson, A.; Phillips, A.; Lundgren, J.; EuroSIDA Study Group.   The use and response to second combination ART regimens in EuroSIDA.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA.
Dalmau, J.;Puertas, M.; Azuara, M.; Marino, A.; Izquierdo-Useros, N.; Buzon, M.; Paredes, R.; Rodrigo, C.; Clotet, B.; Martinez-Picado, J.   Severe primary sexually transmitted HIV infection due to dual-tropic HIV-1.
2008	15th. Conference on Retroviruses and Opportunistic Infections. 03rd-06th February 2008; Boston, USA. [Abstract 83]
Paredes, R.; Lalama, CM.; Ribaudo, HJ.; Schackman, B.; Shikuma, C.; Meyer, WA.; Giguel, F.; Squires, K.; Gulick, RM.; Kuritzkes, DR.   Presence of Minor Populations of Y181C Mutants Detected by Allele-Specific PCR (ASPCR) and Risk of Efavirenz Failure in Treatment-Naïve Patients: Results of an ACTG 5095 Case-Cohort Study.
2008	15th. Conference on Retroviruses and Opportunistic Infections; 03rd-06th February 2008; Boston, USA.
Esté, JA.; Clotet, I.; Bosch, B.; Fernandez-Figueras, M.; Peña, R.; Bofill, M.; Clotet, B.  Phylodynamic analysis of SIV populations in Lymphoid tissues reveals the central role of the Gut-associated lymphoid tissue as a reservoir during suppressive ART.
2008	17th International AIDS Conference. 3rd-8th August 2008; Mexico DF, Mexico. [Abstract ThPe0213].
Muñoz-Moreno, JA.; Fumaz, CR.; Prats, A.; Pérez-Álvarez, N.; Utzet-Sadurní, M.; Ferrer, MJ.; Negredo, E.; Garolera, M.; Clotet, B.  Anxiety Predicts Neurocognitive Complaints in HIV-Infected People.
2008	48th ICAAC. Washington, 23rd-28th October 2008. [Poster V-1665]
Videla, S.; Cañadas, MP.; Darwich, L.; Cirigliano, V.; Garcia Cuyas, F.; Piñol, M.; Castella, E.; Llatjos, M.; Bofill, M.; Clotet, B.; Sirera, G.  Anal human papillomavirus type 16 infection and its integration status by means of a novel multplez real time PC in cytological samples of HIV positive men.
2008	5th Conference on Retroviruses and Opportunistic Infections. Boston, 3rd-6th February 2008. [Abstract 741]
Burger, D.; Eggink, A.; Van der Ende, I.; Hawkins, D.; Vogel, M.; Fatkenheuer, G.; Moltó, J.; Richter, C.; Koopmans, P.; Schutz, M.; and the SARA study group.   The Pharmacokinetics of Saquinavir in New Tablet Formulation + Ritonavir (1000/100 mg Twice Daily) in HIV-1-infected Pregnant Women.
2008	9th International Workshop on Clinical Pharmacology of HIV Therapy. 7th – 9th April 2008; New Orleans, USA.
Moltó, J.; Santos, JR.; Pérez-Álvarez, N.; Cedeño, S.; Miranda, C.; Khoo, S.; Else, L.; Llibre, JM.; Valle.; Clotet, B.   Inhibitory quotient predicts long-term virological response to darunavir-based salvage therapy in HIV-infected protease inhibitor-experienced patients.
2008	9th International Workshop on Clinical Pharmacology of HIV Therapy. 7th – 9th April 2008; New Orleans, USA.
Moltó, J.; Llibre, JM.; Valle, M.; Miranda, C.; Cedeño, S.; Perez-Alvarez, N.; Santos, JR.; Valero, S.; Negredo, E.; Clotet, B.   The effect of nevirapine (NVP) on the steady-state trough concentrations of atazanavir/ritonavir (ATV/rtv).
2008	9th International Workshop on Clinical Pharmacology of HIV Therapy. 7th – 9th April 2008; New Orleans, USA.
Moltó, J.;Llibre, JM.; Ribera, E.; Mínguez, C.; Sánchez del Río, J.; Pedrol, E.; Vallecillo, G.; Cedeño, S.; Valle, M.; Miranda, C.; Negredo, E.; Clotet, B.   Does HCV or HBV Co-Infection Influence Saquinavir Exposure in HIV-Infected Patients without Liver Function Impairment?.
2008	AIDS vaccine 2008. 13th – 16th October 2008. Capetown, South Africa.
Sánchez-Palomino, S.; Massanella, M.; García, A.; Momdedeu, M.; Guilà, T.; García, F.; González, N.; Alcamí, J.; Bofill, M.; Clotet, B.; Gatell, J.; Blanco, J.  New Tools to Quantify Humoral Immune Response against HIV Envelope.
2008	AIDS vaccine 2008. 13th – 16th October 2008; Capetown, South Africa.
Massanella, M.; Puigdomènech, I.; Cabrera, C.; Fernández-Figueras, M.; García, E.; Bofill, M.; Clotet, B.; Blanco, J.   Neutralizing anti-gp41 antibodies fail to block early events of virological synapses but efficiently inhibit infectious cell-to-cell HIV transmission.
2008	HIV DART. December 2008; Puerto Rico.
Negredo, E.; Massanella, M.; Puig, J.; Pérez-Álvarez, N.; Clotet, B and Blanco, J.   Activation of Different Cell Death Pathways in Patients on HAART with Long-term Viral Suppression but Unfavorable Immunologic Response.
2008	II Reunión Annual CIBERER. 19th – 21st November 2008; Valencia.
Negredo, E.; Garrabou, G.; Puig, J.; López, S.; Morén, C.; Bellido, R.; Ayen, R.; Cardellach, F.; Miró, O.; Clotet, B.   artial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
2008	Ninth International Congress on Drug Therapy in HIV Infection 2008. 09th-13th November 2008; Glasgow, UK
Clumeck, N.; Clotet, B.; Johnson, MA.; Peeters, M.; Vingerhoets, J.; Beets, G.; De Smedt, G.   Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials.
2008	Ninth International Congress on Drug Therapy in HIV Infection 2008. 09th-13th November 2008; Glasgow, UK.
Llibre, JM.; Domingo, P.; Blanco, F.; Clotet, B.; Ocampo, A.; García –Henarejos, JA.; Geijo, P.; Rosa, C.; Hernandez-Quero, J.; Castro, A.  Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutations.
2008	Ninth International Congress on Drug Therapy in HIV Infection 2008. 09th-13th November 2008; Glasgow, UK.
Bonjoch, A.; Llibre, JM.; Negredo, E.; Puig, J.; Pérez- Álvarez, N.; Buzón, MJ.; Martinez-Picado, J.; Clotet, B.   Transient therapy with quadruple NRTI provides immune stability in patients with multidrug resistant HIV-1 and no options for suppressive regimens.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13rh November 2008; Glasgow, UK.
Mora, M.; Navarro, C.; Gonzalez-Mena, A.; Rodriguez-Baños, J.; Clotet, B.; Blanco, JL.; Blanco, JR.; Lopez-Bernaldo de Quiros, JC.; Hernandez-Quero, J.; Arazo, P.; Flores, J.; Arribas, JR.   Induction strategy with wnfurvirtide: results from the Funziona study, a multicenter retrospective study in Spain.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK
Bonjoch, A.; Estany, C.; Puig, J.; Echeverría, P.; Caum, C.; Clotet, B.; Negredo, E.  requency of bone abnormalities and associated factors in a Spanich cohort of HIV-infected patients.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Fumaz, CR.; Muñoz-Moreno, JA.; Ferrer, MJ.; Pérez-Álvarez, N.; Moltó, J.; Clotet, B.   Adherence, coping strategies and depression in highly antiretroviral-experienced patients.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Garrabou, G.; Negredo, E.; Morén, C.; Romeu, J.; Rodríguez-Santiago, B.; Nicolàs, M.; Miró, O.; Cardellach, F.; Puig, J.; Pérez-Álvarez, N.; López-Blánquez, R.; Ruiz, L.; Bellido, R.; Miranda, C.; Clotet, B.  Mitochondrial effects of 3 years of CD4-guided HIV treatment interruption.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Fätkenheuer, G.; Clotet, B.; Pialoux, G.; Ruxrungtham, K.; Cohen, C.; Flamm, J.; Vanfeneugden, T.; Lefebvre, E.; Espinosa-Guzman, S.   Safety analysis of darunavir/ (DRV/r): combined data from randomised phase II and phase III studies.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Muñoz-Moreno, JA.; Puig, J.; Fumaz, CR.; Negredo, E.; Ferrer, MJ.; Pérez-Alvarez, N.; González-Mestre, N.; Clotet, B.   Long-Term satisfaction and benefits on quality of life in HIV-infected people after reparatory treatment with Aquamid for facial lipoatrophy.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Ribera, E.; Clotet, B.; Martínez, E.; Estrada, V.; Sanz, J.; Berenguer, J.; Rubio, R.; Pulido, F.; Larrouse, M.; Curran, A.; Negredo, E.; Ferrer, P.; Álvarez, ML.   48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3tC: 48-week interim analysis of the RECOMB trial.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Santos, JR.; Llibre, JM.; Moltó, J.; Perez, N.; García, MC.; Clotet, B.   Efficacy and safety os switching enfuvirtide to raltegravir in patients with viral suppression.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Santos, JR.; Llibre, JM.; Pérez-Álvarez, N.; Domingo, P.; Miralles, C.; Schapiro, J.; Clotet, B.  Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Clotet, B.; Katlama, C.; Lazzarin, A.; Jansen, K.; Kakuda, T.; De Smedts, G.   Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Echeverría, P.; De la Torre, J.; Pasquau, J.; Casas, E.; Puig, T.; Ribera, E.; Bravo, I.; López, R.; Clotet, B.; Negredo, E.; ELA Group.   Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK.
Echeverría, P.; Domingo, P.; Gutierrez, M.; Mateo, G.; Puig, J.; Moltó, J.; Pérez-Álvarez, N.; Clotet, B.; Negredo, E.   Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November 2008; Glasgow, UK. [Oral communication]
Bonjoch, A.; Estany, C.; Negredo, E.; Puig, J.; Echeverria, P.; Caum, C.; Clotet, B.   Frequency of Low Bone Mineral Density and Associated Factors in Spanish Cohort of HIV-Infected Patients on HAART.
2008	Ninth International Congress on Drug Therapy in HIV Infection. 09th-13th November; Glasgow, UK.
Fumaz, CR.; Muñoz-Moreno, JA.; Ferrer, MJ.; Pérez-Álvarez, N.; Moltó, J.; Clotet, B.   Diapositional optimism, perceived health competence and adherence in highly antiretroviral-experienced patients.
2008	SEISIDA. 8-10 de octubre, 2008; Córdoba. (Poster)
Estany, C.; Negredo, E.; Martinez-López, E.; Masabeu, A.; Force, L.; Barrufet, P.; Cucurull, J.; Domingo, P.; Villaverde, CA.; Roca, V.; Echevarría, P.; Cartón, JA.; de la Torre, J.; Galindo, MJ.; Gutierrez, F.; Boix, V.; Pérez-Álvarez, N.; and Clotet, B. from MULTINEKA Group.  Diferentes efectos en la composición corporal entre hombres y mujeres que cambian triple terapia con lopinavir-ritonavir (LPV/rtv) y dos análogos de nucleósidos (NRTIs) a lopinavir-ritonavir más nevirapina (NVP) como terapia de mantenimiento de la infección por el VIH: subestudio MULTINEKA.
2008	XI Congreso Nacional sobre el Sida. 8-10 de octubre, 2008, Córdoba.
Puig, J.; Aldea, D.; Medina, M.;Muñoz-Moreno, JA.; Estany, C.; Clotet, B.; González-Mestre, V.; Negredo, E.   Tratamiento Reparador de la Lipoatrofia Facial con Ácido Poliláctico (Sculptra®).
2008	XIII Congreso SEIMC. Madrid, 11-14 de mayo de 2008.
Cañadas, MP.; Darwich, L.; Videla, S.; Cirigliano, V.; Ordoñez, E.; Castella, E.; Tarrats, A.; Llatjos, M.; Bofill, M.; Piñol, M.; Garcia Cuyas, F.; Clotet, B.; Sirera, G.  Integracion del virus del papiloma humano (VPH) tipo 16 en lesiones anales de hombres infectados con el virus de la inmunodeficiencia humana (VIH).
2008	XIII Congreso SEIMC. Madrid, 11-14 de mayo, 2008.
Ferrer, E.; Saumoy, M.; Ordoñez, J.; Milinkovic, A.; Domingo, P.; Ribera, E.; Negredo, E.; Leibenger, G.; Gatell, JM.; Podzamczer, D.   Perfil metabólico y riesgo cardiovascular estimado tras la sustitución de lopinavir/r por atazanavir/r: Metatazip, sub-estudio del estudio Atazip.
2008	XIII Congreso SEIMC. Mayo 2008, Madrid. [Abstract 214]
Olmo, M.; Niubò, J.; Peñaranda, M.; Gutiérrez, F.; Romeu, J.; Larrousse, M.; Domingo, P.; Oteo, JA.; Sánchez, P.; Ruiz, I.; Ruiz, L.; Villalonga, C.; Bernal, E.; Aldeguer, JL.; Iribarren, J.; Podzamczer, P.; y grupo del estudio STOPAR.   Mutaciones de resistencia en plasma y en células mononucleares de sangre periférica durante un estudio randomizado de interrupción de tratamiento guiado por CD4: resultados a la semana 96.
2008	XIII Congreso SEIMC. Mayo 2008, Madrid. [Abstract 226]
Olmo, M.; Peñaranda, M.; Niubò, J.; Gutiérrez, F.; Romeu, J.; Larrousse, M.; Domingo, P.; Oteo, JA.; Sánchez, P.; Ruiz, I.; Ruiz, L.; Villalonga, C.; Bernal, E.; Aldeguer, JL.; Iribarren, J.; Podzamczer, P.; y grupo del estudio STOPAR.  Ensayo randomizado de interrupción de tratamiento guiada por CD4 en pacientes tratados mayoritariamente con INNTI: resultados a la semana 96.
2008	XVII International AIDS Conference 3rd-8th August 2008; Mèxic DF , Mèxic. [Abstract CDB0461]
Estany, E.; Negredo, E.; Martinez-López, E.; Masabeu, A.; Force, L.; Barrufet, P.; Cucurull, J.; Domingo, P.; Villaverde, CA.; Roca, V.; Echevarría, S.; Cartón, JA.; de la Torre, J.; Galindo, MJ.; Gutierrez, F.; Boix, V.; Pérez-Álvarez, N.; and Clotet, B. from MULTINEKA Group.   Different effects on body composition between men and women switching triple therapy with lopinavir-ritonavir (LPV/rtv) and two nucleoside analogs (NRTIs) to lopinavir-ritonavir plus nevirapine (NVP) for maintenance therapy of HIV infection: MULTINEKA substudy.
2008	XVII International AIDS Conference. 3rd-8th August 2008; Mexico DC, Mexico. [Poster Number THPE0157].
Negredo, E.; Miró, O.; Garrabou, G.; Morén, C.; Cardellach, F.; Estany, C.; Rodríguez-Santiago, B.; Puig, J.; Masabeu, A.; Force, L.; Barrufet, P.; Cucurull, J.; Domingo, P.; Alonso, C.; Pérez-Álvarez, N.; and Clotet, B.   Lopinavir-ritonavir plus nevirapine as a strategy to improve nucleoside-related mitochondrial toxicity in chronically treated HIV-infected patients: 48 week follow-up of MULTINEKA study.
2008	XVII International AIDS Conference. 3rd-8th August 2008; Mexico DC, Mexico. [Poster THPE0162].
Negredo, E.; Puig, J.; Perez-Alvarez, N.; Utzet-Sadurni, M.; Muñoz, J.; Fumaz, CR.; et al.   Four Year-Experience of Polyacrylamide Gel (Aquamid®) for facial lipoatrophy treatment.
2008	XVII International AIDS Conference. 3rd-8th August 2008; Mexico DC, Mexico. [Poster THPE0178]
Negredo, E.; Gallego-Escudero, JM.; Puig, J.; Giralt, M.; Blanco, J.; Clotet, B.; and Villarroya, F.   High apoptotic activity as final pathogenic mechanism of CD4 cell decline in patients receiving high doses of ddI and tenofovir.
2008	XVII International AIDS Conference. 3rd-8th August 2008; Mexico DF, Mexico. [Poster MOPDB102]
Martínez, E.; Ribera, E.; Pulido, F.; Rubio, R.; Negredo, E.; Sanz, J.; et al.  Early Improvement of Limb Fat Content in Patients Switching from AZT/3TC to FTC/TDF (TVD): A Week 24 Interim Analysis of the RECOMB Trial.
2008	XXIVth International Biometric Conference. 13th July 2008, Dublin.
Pérez-Álvarez, N.; Konings, P.; Van Steen, K.; Tahri, N.  Analysis of an outcome beyond a detection limit: application to HIV RNA data.
2007	11th European AIDS Conference/EACS. 24th-27th October. Madrid (Abstract P11.6/03)
Falco, V.; Olmo, M.; Villar del Saz, S.; Guelar, A.; Santos, JR.; et al.  Influence of HAART on the clinical course of patients with progressive multifocal leukoencephalopathy. Results of an observational multicenter study.
2007	11th European AIDS Conference/EACS. 24th-27th October. Madrid (Abstract P3.4/05)
Llibre, JM.; Puig, T.; Martinez-Picado, J.; Santos, JR.; Bravo, I.; Shafer, RW.; Schapiro, J.; Clotet, B.  Predicted resistance to Tipranavir and Darunavir in clinical samples from 1999-2006 with protease resistance mutations.
2007	11th European AIDS Conference/EACS. 24th-27th October. Madrid.
Negredo, E.; Holstrom, M.; Puig, J.; Giralt, M.; Blanco, J.; Clotet, B.; Villaroya, F.  High apoptopic activity as final pathogenic mechanism of CD4 cell decline in patients receiving high doses of ddl and tenofovir.
2007	11th European AIDS Conference/EACS. 24th-27th October. Madrid.
Negredo, E.; Puig, J.; Perez-Alvarez, N.; Utzet-Sadurní, M.; Fumaz, CR.; Aldea, D.; Estany, C.; Gonzalez-Mestre, V.; Clotet, B.  Long-term security of Polyacrylamide Gel (Aquamid): a mean experience of 4 years.
2007	11th European AIDS Conference/EACS. 24th-27th October. Madrid. (P17.1/27)
Pedrol, E.; Negredo, E.; Domingo, P.; Estrada, V.; Flores, J.; Echevarría, S.; Minguez, C.; Terrón, A.; Llibre, JM.; Peralta, G.; Ocampo, A.; Deig, E.  Study of changes in CD4 cells count after switching tenofovir to abacavir or TDF and didanosine to ABC+lamivudine in patients with a ddI + TDF containing regimen and viral supression (Europa study): final results.
2007	14th Conference on Retroviruses and Opportunistic Infections. 25th-28th February, Los Angeles (USA)
Sirera, G.; Ballesteros, AL.; Piñol, M.; Cañadas, MP.; LLatjós, M.; Videla, S.; Garcia-Cuyàs, F.; Castellà, E.; Guerola, R.; Clotet, B.  Low concordance between citological and histological results for screening of anal dysplasia in HIV-patients.
2007	14th Conference on Retroviruses and Opportunistic Infections. 25th-28th February, Los Angeles (USA)
Franco, S.; Parera, M.; Aparicio, E.; Clotet, B.; Martinez, MA.  Genetic and phenotypic structure of hepatitis C virus NS3/4 protease quasispecies.
2007	14th Conference on Retroviruses and Opportunistic Infections. 25th-28th February, Los Angeles (USA)
Cedeño, S.; Llano, A.; Clotet, B.; Bofill, M.; Este, JA.  CD4 + CD45R0 + CD127 - CCR55+ cells define the expansion of CD127-T cellsin HIV+ individuals.
2007	14th Conference on Retroviruses and Opportunistic Infections. 25th-28th February, Los Angeles (USA). (Abstract 383)
Muñoz-Moreno, JA.; Fumaz, CR.; Prats, A.; Ferrer, MJ.; Negredo, E.; Garolera, M.; Clotet, B.  Recommended Earlier Initiation of Art Based on Nadir CD4 Cell Count as a risk factor for HIV-related neurogognitive impairment.
2007	14th International Workshop on HIV Dynamics and evolution. Segovia (Spain)
Fernandez, G.; Clotet, B.; Martinez, MA.  Fitness landscape of HIV-1 protease quasispecies.
2007	16th International AIDS Conference. 13th-18th August, Toronto (Canada). (Abstract WePe0249)
Fumaz, CR.; Muñoz-Moreno, JA.; Mendez, J.; Ferrer, MJ.; Lopez-Blazquez, R.; Negredo, E.; Gomez, G.; Tarrats, A.; Clotet, B.  Sexual dysfunction is not related to immunologic status in HIV-infected women.
2007	1st International symposium on Genetic and Immune Correlates of HIV infection and Vaccine-Induced Immunity. 10th-13th June, Budapest (Hungary)
Bofill, M.; Darwich, L.; Cabrera, C.; Martinez-Picado, J.; Este, JA.; Clotet, B.; Ruiz, L.  CD4 T helper Responses to CMV Predict the Time "Off Therapy" in HIV-infected patients under guided treatment interruptions.
2007	20th International Conference on Antiviral Research. 29th April-3rd May, Palm Springs, California (USA).
Moncunill, C.; Arman-Ugón, M.; Pauls, E.; Clotet, B.; Esté, JA.  HIV Coreceptor Switch Induced by Antagonism to CCR5.
2007	20th International Conference on Antiviral Research. 29th April-3rd May, Palm Springs, California (USA).
Pauls, E.; Senserich, J.; Bofill, M.; Clotet, B.; Este, JA.  Induction of interleukins IL-6 and IL-8 by siRNA.
2007	24th International Papillomavirus Conference & Clinical Workshop. 3rd-9th November, Beijin (China)
Cañadas, MP.; Cirigliano, V.; Videla, S.; Ejarque, M.; Ordoñez, E.; Darwich, L.; Voglino, G.  Human Papillomavirus (HPV) study of 3058 cytological samples by a new multiplex f-HPV typing PCR: genotype distribution from an italian population.
2007	24th International Papillomavirus Conference & Clinical Workshop. 3rd-9th November, Beijin (China)
Sirera, G.; Videla, S.; Romeu, J.; Cañadas, MP.; Darwich, L.; Fernandez, MT.; Balo, S.; Cirauqui, B.; Bofill, M.; Ejarque, M.; Rey-Joly, C.; Clotet, B.  Fatal fast-evolution of nasopharyngeal squamous cell carcinoma in an HIV-patient with Epstein-barr and two high risk oncogenic Human Papilloma viruses (-16 and -33) in blood serum.
2007	24th International Papillomavirus Conference & Clinical Workshop. 3rd-9th November, Beijin (China)
Darwich, L.; Cañadas, MP.; Videla, S.; Castella, E.; Tarrats, A.; Llatjos, M.; Alcalde, C.; Bofill, M.; Clotet, B.; Sirera, G.  Prevalence, incidence, persistance and clearance of cervical human papillomavirus infection in an HIV-positive cohort without previous cervical pathology by both Hybrid Capture and Multiplex-PCR techniques.
2007	24th International Papillomavirus Conference & Clinical Workshop. 3rd-9th November, Beijin (China)
Cañadas, MP.; Darwich, L.; Videla, S.; Cirigliano, V.; Rueda, L.; Castella, E.; Tarrats, A.; Llatjos, M.; Alacalde, C.; Bofill, M.; Piñol, M.; Garcia-Cuyas, F.; Clotet, B.; Sirera, G.  Human Papillomavirus type 16 integration status in anal intraepitelial neoplasia biopsies of Human Immunodeficiecy Virus (HIV)-infected males by multiplex real-time PCR.
2007	25th-30th March. Whistler (Canada)
Clotet-Codina, I.; Bosch, B.; Peña, R.; Clotet, B.; Bofill, M.; Este, JA.  DC-SIGN is not required for HIV-1 transmission to CD4+T lymphocytes. Keystone Symposia Molecular and cellular determinants of HIV pathogenesis.
2007	2nd International Conference on HIV Treatment Adherence. 28th-30th March, Jersey City (USA). (Abstract 138)
Fumaz, CR.; Muñoz-Moreno, JA.; Ferrer, MJ.; Moltó, J.; Lopez-Blazquez, R.; Negredo, E.; Clotet, B.  Variables that promote adherence in highly antiretroviral-experienced patients. BEAT study.
2007	3rd Meeting Targeting HIV Entry. 7th-8th December, Washington (USA)
Cabrera, C.; Marfil, S.; Garcia, E.; Ruiz, L.; Bofill, M.; Clotet, B.; Blanco, J.  Changes in the gp120 protein restore replicative capacity in low-fitness N43D gp41 mutants.
2007	47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September, Chicago (USA).
Sirera, G.; Videla, S.; Lopez-Blazquez, R.; Llatjós, M.; Tarrats, A.; Castellà, E.; Grane, N.; Alcalde, C.; Tural, C.; Rey-Joly, C.; Clotet, B.   HAART and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and above 350 Cd4 cell counts.
2007	4th Conference of the Eastern Mediterranean Region of the International Biometric Society (Emr-Ibs). 23rd-25th January, Elat, Israel (Poster).
Perez-Alvarez, N.; Gomez, G.; Ruiz, L.; Clotet, B.  Study of the Cd4 cell counts evolution during the 1st, 2nd and 3rd period without treatment in a HIV Clinical TRial.
2007	4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22nd-25th July, Sidney (Australia).
Olmo, M.; Podzamczer, D.; Niubò, J.; Peñaranda, M.; Gutierrez, F.; Ruiz, L.; Romeu, J.; Larrouse, M.; Domingo, P.; Oteo, J.; for the STOPAR team.  PBMC and plasma genotypic resistance during CD4-guided HAART interruption in patients receiving mainly NNRTI-based regimens.
2007	4th Intl AIDS Society Conference on HIV Patogenesis, Treatment and Prevention. 22nd-25th July, Sidney (Australia). (Track B Late Breaker Session 1, WESS102).
Martinez, E.; Arranz, JA.; Podzamczer, D.; Ribera, E.; Knobel, H.; Roca, V.; Gutierrez, F.; Llibre, JM.; Clotet, B.; Dalmau, D.; Pich, J.; De Lazzari, E.; Gatell, JM. for the BICOMBO study group.  Efficacy and safety of tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic supression receiving a lamivudine containing HAART: The BICOMBO study.
2007	8th International Workshop on Clinical Pharmacology of HIV Therapy. 16th-18th April, Budapest (Hungary).
Moltó, J.; Valle, M.; Miranda, C.; Blanco, A.; Santos, JR.; Negredo, E.; Vilaró, J.; Clotet, B.  Population pharmacokinetics of Nevirapine in HIV-Infected adults.
2007	8th International Workshop on Clinical Pharmacology of HIV Therapy. 16th-18th April, Budapest (Hungary). (Poster)
Moltó, J.; Valle, M.; Fumaz, CR.; Santos, JR.; Negredo, E.; Blanco, A.; Perez-Alvarez, N.; Clotet, B.  Evidence of pharmacodynamic tolerance to efavirenz-related neuropsychiatric side effects.
2007	AIDS Vaccine. 20th-23rd August, Seattle (USA).
Massanella, M.; Puigdomènech, I.; Fiernandez-Figueras, MT.; Bofill, M.; Clotet, B.; Blanco, J.  Broadly neutralizing antibodies against gp41 fail to block the formation of virological synapses. A potential mechanism of HIV escape.
2007	Cold Spring Harbour Retrovirology Meeting. 22nd-27th May, New York.
Senserrich, J.; Pauls, E.; Clotet-Codina, I.; Arman-Ugón, M.; Moncunill, G.; Clotet, B.; Esté, JA.  HIV-1 resistance to the anti-HIV activity of siRNA targeting Rev.
2007	IAS Conference. Sidney (Australia)
Echeverría, P.; Alonso, M.; Portilla, J.; Ocampo, A.; Pedrol, E.; Carosi, E.; Perez-Alvarez, N.; Bravo, I.; Clotet, B.; Negredo, E.  Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir administered with abacavir/lamivudine (kivexa) in antiretroviral-naïve patients: a multicentre, randomized study (LAKE STUDY).
2007	International Workshop on Statistical Modelling. 2nd-6th July, Barcelona. (Poster)
Perez-Alvarez, N.; Gomez, G.; Ruiz, L.; Clotet, B.  Study of the 1st, 2nd and 3rd guided interruption periods in a HIV clinical trial.
2007	IX Congreso Nacional de Virología. Zaragoza (Spain)
Franco, S.; Parera, M.; Aparicio, E.; Clotet, B.; Martinez, MA.  Estructura en cuasiespécies de la proteasa NS3/4a del virus de la hepatitis C (VHC), a nivel genotípico y fenotípico.
2007	Jornada de virología. 3 de Noviembre, Barcelona.
Massanella, M.; Puigdomènech, I.; Fernandez-Figueras, MT.; Bofill, M.; Clotet, B.; Blanco, J.  Broadly neutralizing antibodies against gp41 fail to block the formation of virological synapses. A potential mechanism of HIV escape.
2007	Keystone Symposium on HIV Patogenesis. Keystone (USA)
Clotet-Codina, I.; Bosch, B.; Peña, R.; Clotet, B.; Bofill, M.; Este, JA.  DC-SIGN is not required for HIV-1 transmission to CD4+ T lymphocytes.
2007	The 8th International Congress on Drug Therapy in HIV Infection. 13th-16th November, Glasgow (UK). (Abstract P171)
Fumaz, CR.; Muñoz-Moreno, JA.; Ferrer, MJ.; Lopez-Blazquez, R.; Moltó, J.; Negredo, E.; Gomez, G.; Clotet, B.  Different adherence levels do not influence on CD4 cell count in very long antiretroviral experienced patients: BEAT study.
2007	XI Conferencia Española y I Encuentro Iberoamericano de Biometría. 20-22 de Junio, Salamanca.
Perez-Alvarez, N.; Muñoz-Moreno, JA.; Gomez, G.; Fumaz, CR.; Ferrer, MJ.; Clotet, B.  Classifying adherence to antiretroviral treatment in HIV-infected patients.
2007	XI Conferencia Española y I Encuentro Iberoamericano de Biometría. 20-22 de Junio, Salamanca.
Perez-Alvarez, N.; Negredo, E.; Comez, G.; Rodriguez-Santiago, B.; Miró, O.; Clotet, B.  Study of the mitochondria function during an HIV Interruption treatment.
2007	XVI International HIV Drug Resistance Workshop. 12th-16th June, Bridgetown (Barbados)
Llibre, JM.; Santos, JR.; Puig, T.; Moltó, J.; Ruiz, L.; Clotet, B.  Prevalence of Etravirine-associated mutations in clinical samples with resistance to Nevirapine and Efavirenz.
2007	XVI International HIV Drug Resistance Workshop. 12th-16th June, Bridgetown (Barbados)
Llibre, JM.; Bonjoch, A.; Iribarren, JA.; Galindo, MJ.; Martinez-Picado, X.; Santos, JR.; et al.  Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir and Tenofovir with persistent viral replication.
2007	XVI International HIV Drug Resistance Workshop. 12th-16th June, Bridgetown (Barbados)
Darwich, L.; Bellido, R.; Blanco, A.; Ruiz, L.; Esteve, A.; Cabrera, C.; Moltó, J.; Martinez-Picado, J.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) plasma concentrations determine different NNRTI-resistance pattern in virological responders during treatments interruptions.
2007	XVI International HIV Drug Resistance Workshop. 12th-16th June, Bridgetown (Barbados). (Poster 70)
Mallolas, J.; Riera, M.; Domingo, P.; Knobel, H.; Pedrol, E.; Gutierrez, F.; Barrufet, P.; Peraire, J.; Dalmau, D.; Ribera, E.; Ocampo, A.; Muniain, MA.; Alonso, C.; Estrada, V.; Blanco, JR.; Cucurull, J.; Pich, J.; de Lazzari, E.; Llibre, JM.; Carmena, J.; Galindo, MJ.; Gatell, JM. for de Trizefal Study Group.  Selection of resistance mutations in a randomized trial testing and induction maintenance strategy with trizivir plus either efavirenz or lopinavir/r during the induction period.
2007	XXII Congreso Nacional de la SENPE. 31 de mayo-1 de junio, Sevilla
Estany, C.; Martinez-Lopez, E.; Lopez-Blazquez, R.; Tural, C.; Salas, A.; Cantón, A.; Sanmartí, A.; Clotet, B.  Cambios antropométricos en pacientes coinfectados por VIH/VHC que realizan tratamiento de inducción con interferón y ribavirina.
2007	XXII Congreso Nacional de la SENPE. 31 de mayo-1 de junio, Sevilla
Estany, C.; Martinez-Lopez, E.; Lopez-Blazquez, R.; Tural, C.; Salas, A.; Cantón, A.; Sanmartí, A.; Clotet, B.  Cambios antropométricos en pacientes coinfectados por VIH/VHC en tratamiento con interferón pegilado y ribavirina y que interrumpen antiretrovirales.
2007	XXII Congreso Nacional de la SENPE. 31 de mayo-1 de junio, Sevilla. (Poster)
Martinez, E.; Estany, C.; Negredo, E.; Lopez, R.; Cantón, A.; Sanmartí, A.; Clotet, B.  Cambios morfológicos en pacientes infectados por VIH tras 42 meses de interrupción del tratamiento antiretroviral de gran actividad.
2007	XXXIII Congreso Sociedad Española Inmunología (SEI). 28-31 de marzo; Granada
Puigdomènech, I.; Joan, M.; Clotet, B.; Blanco, J.  Adhesion molecules modulate the formation and function of virological synapses and determine increased susceptibility of CD45RO CD4 T cells.
2007	XXXIII Congreso Sociedad Española Inmunología (SEI). 28-31 de marzo; Granada
Coma, G.; Peña, R.; Clotet, B.; Blanco, J.; Bofill, M.  IL-12 e IL-18 aumentan la supervivencia en monocitos de sangre periférica.
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 234) Denver, Colorado
N Izquierdo , J Blanco, M Fernández-Figueras , I Erkizia , P Parrales , L Ruiz, B Clotet, J Martínez-Picado   Mature Monocyte-derived Dendritic Cells Capture and Trans-infect HIV-1 Independently of DC-SIGN
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 267) Denver , Colorado
M Gimenez-Barcons , R Sabariegos , N Tapia , B Clotet , M Martinez   HIV-1 Sequence Homology Requirements to Escape from Short Interfering RNA
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 512) Denver , Colorado
B Bosch , I Clotet-Codina , J Blanco , G Comma , S Cedeño , F Mitjans , J Piulats , M Bofill , B Clotet , J A Este  Interference of A-v Integrins Blocks HIV-1 Infection in Macrophages
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 514) Denver , Colorado
E Pauls , B Clotet , M Bofill , J A Este   siRNA-directed against HIV Co-receptor CCR5 Modulate IL-6 and IL-8 Secretion in a Sequence-specific Manner
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 604) Denver, Colorado
A Cozzi-Lepri , L Ruiz , F Ceccherini-Silberstein , A Mocroft , A Phillips , J Gatell , B Ledergerber , P Reiss , B Clotet , J Lundgren , EuroSIDA Study Group   Mutation at Reverse Transcriptase Codon 214 is Antagonist to Thymidine Analogue Mutations Type 2 Profiles and Predicts Virological Response to Thymidine Analogue-contaning cART Regimens only if TAM Type 1 Profiles Are Concomitantly Detected
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 758) Denver, Colorado
E Negredo , B Rodriguez-Santiago , J Puig , R Lopez-Blazquez , R Ayen , E Martinez-Lopez , C Miranda , L Ruiz , B Clotet   Effect of Prolonged Interruption of ART on Mitochondrial Toxicity
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 806) Denver, Colorado
G Sirera , A Ballesteros , M Piñol1 , M Cañadas , M Lletjós , S Videla , F García-Cuyás , E Castellà , R Guerola , B Clotet   High Prevalence of Human Papilomavirus (HPV) Infection in Male Positive for Human Inmunodeficiency Virus (HIV), even without Anal Intraepitelial Lesions (SILs)
2006	02/05-02/08. 13th Conference on Retroviruses and Opportunistic Infections (Abstract 863) Denver , Colorado
C Tural , M Romero , R Sola , R Planas , M Viloria , M Gimenez , A Arrizcorreta , C Trabadela , B Clotet   Insulin Resistance Is a Prognostic Factor of Poor Response to Peg-interferon-Alpha 2a + Ribavirin in HCV+/HIV+ Patients
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-276). Boston, USA
B Bosch, J Blanco, M Fernández-Figueras, B Clotet, J Esté   Inhibition of co-receptor independent cell-to-cell HIV-1 transmission.
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-611). Boston, USA
A Esteve, A Jaen, J Casabona, J Miró, M Riera, E Ferrer, C Tural, F Segura, L Force, O Sued, J Vilaró, A Masabeu, C Villalonga, A Podzamczer, B Clotet and PISCIS Study Group  Long-term immunologic reconstitution (4 years) in Spanish HIV-infected patients on HAART in the PISCIS Cohort Study
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-679). Boston, USA
L Ruiz, J Romeo, J Martínez-Picado, R Bellido, J Llibre, P Domingo, G Tambussi, B Clotet on behalf of the Tibet Study Group.   Selection of Drug-resistance mutations in chronic HIV-infected patients during therapy interrupcions guided by CD4+T- cell counts and viral load levels: the TIBET Study.
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-691). Boston, USA
J Martínez-Picado, T Wrin, S Frost, B Clotet, L Ruiz, A Leigh Brown, C Petropoulos, N Parkin.  Phenotypic Hypersusceptibility to multiple protease inhibitors and low replicate capacity in chronically HIV-1-infected patients.
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-718). Boston, USA
C Cabrera, E García, S Marfil, J Martínez-Picado, A Bonjoch, E Grau, C Gutierrez, M Pérez-Elias, S Moreno, B Clotet, L Ruiz.   Genotypic evolution of T-20 resistance associated mutations in heavily treated HIV-1 infected patients on long-term treatment with T-20
2005	02/22-02/25 12th. Conference on Retroviruses and Opportunistic Infections. (M-926). Boston, USA
M Opravil, J Sasadeusz, D Cooper, J Rockstroh, N Clumeck, B Clotet, J Montaner, F Torriani, J dePamphilis and D Dieterich.   Effect of baseline CD4 count on efficacy and safety of Pegylated Interferon-2a (PEGASYS) plus ribavirin in HIV/HCV co-infection: The AIDS PEGASYS ribavirin international co-infection trial (APRICOT)
2005	03/30-04/01 3rd. European HIV Drug Resistance Workshop (Poster 14) Athens, Greece
C Gutierrez, C de Mendoza, I Erkicia, P Domingo, X Camino, MJ Galindo, JL Blanco, M Leal, A Masabeu, A Guelar, JM Llibre, N Margall, J Iribarren, S Gutierrez, JF Baldoví, JD Pedreira, JM Gatell, S Moreno, B Clotet, V Soriano, and L Ruiz on behalf of the Maraton TV3 Study Group.  Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during year 2004.
2005	03/30-04/01 3rd. European HIV Drug Resistance Workshop (Poster 61) Athens, Greece
C Cabrera, E García, S Marfil, J Martínez-Picado, A Bonjoch, E Grau, J Romeo, B Clotet, L Ruiz.  Genotypic evolution of T20 resistance associated mutations in heavily treated HIV infected patients on long term treatment with T-20.
2005	04/10-04/14 The 18th. International Conference on Antiviral Research. Barcelona, Spain
Mercedes Armand-Ugón, Imma Clotet, Cristina Tintori, Fabrizio Manetti, Bonaventura Clotet, Maurizio Botta, JA Esté   Homology Modeling of HIV-1 gp120 and Docking of Molecules on its Surface Agree with Experimental Data
2005	04/10-04/14 The 18th. International Conference on Antiviral Research. Barcelona, Spain
Julia Blanco, Imma Clotet, Bonaventura Clotet, Jose A. Esté   A Multiparametric Assay to Screen and Dissect the Mode of Action of Anti-HIV Envelope Drugs
2005	04/10-04/14 The 18th. International Conference on Antiviral Research. Barcelona, Spain
Eduardo Pauls, Jordi Senserrich, Bonaventura Clotet, José A. Esté   RNA Interference of p53 Blocks HIV Replication
2005	04/10-04/14 The 18th. International Conference on Antiviral Research. Barcelona, Spain
Berta Bosch, Julia Blanco, Maria T. Fernandez-Figueras, Bonaventura Clotet, José A. Esté   Inhibition of CD4-gp120 Binding Blocks Coreceptor Independent Cell to Cell HIV-1 Transmission
2005	04/28-04-30 6th International Workshop on Clinical Pharmacology of HIV Therapy. (Abstract 36). Quebec, Canada
J Moltó, M Valle, A Blanco, J Miranda, C Miranda, N Pérez-Alvarez, S Gel, E Negredo, G Sirera, B Clotet.   Exposure to lopinavir (LPV) among HIV/HCV co-infected patients without liver function impairment.
2005	04/28-04-30 6th International Workshop on Clinical Pharmacology of HIV Therapy. (Abstract 70). Quebec, Canada
J Moltó, A Blanco, C Miranda, J Miranda, J Puig, M DelaVarga, M Valle, E Negredo, B Clotet.   Variability in antiretroviral agents concentrations in plasma among HIV infected adults in routine clinical practice.
2005	04/28-04-30 6th International Workshop on Clinical Pharmacology of HIV Therapy. (Abstract 90). Quebec, Canada
M Kurowski, J Moltó, A Breske, G Kruse, H Stocker, M Becker, A Hill, C Möcklinhoff, B Clotet.   Atazanavir (ATV) enhances trough concentrations of Nelfinavir (NFV) and its M8 metabolite in a treatment regimen without ritonavir (RTV).
2005	05/10-05/13 XXXI Congreso de la Sociedad Española de Inmunologia. Córdoba, Spain
Coma G, Peña R, Rosell A, Clotet B, Bofill M.   Interleukine-12 and interleukine-18 have a synergistic effect on the production of inflammatory chemokines by monocytes and macrophages in vitro.
2005	06/16-06/17 14th Meeting of the Population Approach Group in Europe. Pamplona, Spain
J Moltó, M Valle, A Blanco, M Delavarga, C miranda, J Miranda, J Costa, MJ Barbanoj, B Clotet.   Population pharmacokinetics of lopinavir in HIV-infected adults receiving lopinavir/ritonavir.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract MoPe15.1C15. Rio de Janeiro, Brazil
Muñoz-Moreno JA, Fumaz CR, Prats A, Ferrer MJ, Negredo E, Moltó J, López-Blázquez R, Gómez G, Garolera M, Clotet B   Influence of Nadir CD4+ Cell Count in Neuropsychological Functioning of HIV-Infected Patients
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract TuPe.2.4C11. Rio de Janeiro, Brazil
Bonjoch A.,Martinez-Lopez E, Galvez J., Miralles C., de la Torre J., Prieto A.,Vilades C, Clotet B.   Evaluation of lipodystrophy syndrome in HIV-infected patients after simplification from first-line antiretroviral treatment with Trizivir™ and Combivir™ plus nevirapine. SimplifiHAART substudy.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract TuPe1.1C25. Rio de Janeiro, Brazil
Perez-Elias MJ, Gatell JM, Flores J, Santos J, Vera FJ, Clotet B, Moreno A, Vendrell B, Perez-Molina JA, Alvarez C, Ledesma E, Serrano O  Effect Of Ritonavir-Boosted Atazanavir (Atv/R) In Experienced HIV-Infected Patients Regarding Chronic Hepatitis B/C Status.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract TuPe1.1C35. Rio de Janeiro, Brazil
Muñoz-Moreno JA, Fumaz CR, Prats A, Ferrer MJ, Negredo E, Moltó J, López-Blázquez R, Gómez G, Garolera M, Clotet B  Differences in Neuropsychological Functioning between HIV+ and HIV+/HCV+ Infected Patients
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract TuPe2.4C17. Rio de Janeiro, Brazil
Martinez-Lopez E, Negredo E, Miranda C, Perez-Alvarez N, Canton A, Estany C, Puig J, Miranda J, Ruiz L, Sanmartí A, Clotet B   Impact of antiretroviral treatment interruption on morphologic changes. The Tibet substudy.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract TuPe6.1B10. Rio de Janeiro, Brazil
Moncunill G, Negredo E, Vilarrasa J, Clotet B, Esté JA  Evaluation of the anti-HIV activity of statins
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.2C22. Rio de Janeiro, Brazil
Martinez-Lopez E, Perez-Alvarez N, Negredo E, Canton A, Estany C, Clotet B, Sanmartí A   Relationship between morphologics changes and immune status
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.3C10. Rio de Janeiro, Brazil
Bonjoch A, Puig J, Miranda C, Erkizia I, Perez-Alvarez N, Puig T, Ruiz L, Clotet B   Early Viral rebound after enfuvirtide discontinuation in HIV-infected patients on long lasting viral suppression.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.3C16. Rio de Janeiro, Brazil
Barrios A, Negredo E, Vilaro J, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Galvez J, Santos J, Terron JA, Casas E, Riera M, Vergara A, Perez-Guzman E, Galindo M.J, Maida I, Martin-Carbonero L, Barreiro P, Nuñez M, Blanco F, Garcia-Benayas T, Gonzalez-Lahoz J, Clotet B, Soriano V   Efficacy and Safety of a QD Simplification Regimen with Didanosine plus Tenofovir plus Efavirenz – Final results of the EFADITE Trial
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.3C18. Rio de Janeiro, Brazil
JA Muñoz-Moreno, CR Fumaz, A Bonjoch, MJ Ferrer, J Miranda, B Clotet.   Impact of Two Simplified Therapies on Quality of Life and Adherence in HIV-Infected patients with Undetectable Viral Load. SimplificHaart Study.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.7C29. Rio de Janeiro, Brazil
Lopez J, Moreno S, Jimenez-Oñate F, Clotet B, Rubio R, Hernandez-Quero J  Effects of taking didanosine capsules (ddI-EC) with and without food on virological failure and treatment discontinuation: The FOODDIe Study.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.9C05. Rio de Janeiro, Brazil
Bonjoch A, Miranda C, Puig J, Perez-Alvarez N, Clotet B.   Long lasting viral efficacy and safety of Enfuvirtide containing therapy in HIV-1 Spanish infected patients.
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe12.9C05. Rio de Janeiro, Brazil
Fernández-Cruz E, Clerici M, Abad M, Carbone J, Rodriguez-Sainz C, Moreno S, Bouza E, Peña J, Podzamczer D, Ocaña I, Clotet B, Rubio R, Pulido F, Viciana P, Maradona J, Carton J, Quereda C, Blazquez R, Barros C, Ferrer E, Díaz M, Jou A, Sirera G, Gil J, Condés E, Muñoz-Fernandez M, Diaz L, Gatell JM, Garcia-Sanchez F, Vicario J, Lopez F, Gonzalez-Lahoz J, Martín-Carbonero L, Santamaría B, Navarrro J, STIR 2102 Team   Therapeutic immunization with an HIV-1 immunogen (REMUNE) induces HIV-1-specific responses against HIV-1 antigens and alloresponses against HLA-alloantigens
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe6.3C14. Rio de Janeiro, Brazil
Harris M, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B Singer J, Montaner J  Abstract: NRTI Sparing Trial (CTN 177): Antiviral and metabolic effects of nevirapine (NVP) + lopinavir/ritonavir (LPV/r) vs. zidovudine/lamivudine (AZT/3TC) + NVP vs. AZT/3TC + LPV/r
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePe8.9B05. Rio de Janeiro, Brazil
Pauls E, Senserrich J, Clotet B, Esté JA  RNA interference of p53 blocks HIV replication without affecting envelope function
2005	07/24-07-27 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract WePp0402. Rio de Janeiro, Brazil
Fernandez-Cruz E, Moreno S, Navarro J, Podzamczer D, Rodriguez Sainz C, Bouza E, Viciana P, Ocaña I, Clotet B, Rubio R, Pulido J, Maradona JA, Carton J, Quereda C, Blazquez R, Gil J, Valor L, Ferrer E, Dìaz M, Jou A, Sirera G, Carbone J, Peña JM, Gijón P, Gatell JM, Lopez F, Desco M, Santamaría B, Calvo P, Gómez V, Camino I, Gonzalez Lahoz J, REMIT Team  Results of the Spanish phase II trial with a therapeutic vaccine: enhancement of CD4 and CD8 specific immune responses against HIV-1 antigens may allow control of viral load during antiviral drug treatment interruption in HIV-1+ individuals treated with an HIV-1 immunogen
2005	09/16-09/19. VII Congreso Nacional de Virología . Valencia , Spain
N Tapia , M Cabana , B Clotet , M A Martínez  Caracterización de la actividad y fenotipo de la protease del VIH-2 mediante un sistema de screening genético basado en el bacteriófago lambda.
2005	10th European AIDS Conference / EACS Dublin. November 17-20, 2005. PE17.4/2.
Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD.   Evolution of drug resistance in HIV infected patients.
2005	11/17-11/20 10th European AIDS Conference / EACS (Poster no. PE17.5/2). Dublin, Ireland
W Bannister, L Ruiz, B Ledergerber, A Cozzi-Lepri, O Kirk, S Staszewski, C Loveday, B Clotet, A Phillips, J Lundgren for the EuroSIDA study group.   Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA.
2005	11/17-11/20 10th European AIDS Conference / EACS (Poster no. PE7.3/20). Dublin, Ireland
J Moltó, J Muñoz-Moreno, J Miranda, R Martínez-López, E Negredo, B Clotet.   Safety and efficacy of once vs. twice-daily antiretroviral therapy with lopinavir/ritonavir plus abacavir and tenofovir among HIV infected adults without previous treatment experience.
2005	12/16-12/19 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. (ICAAC, Abstract 2507). Washington, USA
E. Negredo. J. Blanco, J. Puig, L. Ruiz, J. Romeu, C. Rey-Joly, B. Clotet  May Statins Inhibit In Vivo HIV-1 Replication?
2005	12/16-12/19 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. (ICAAC, Abstract 349). Washington, USA
J Moltó, L Ruiz, M Valle, A Bonjoch, J Martinez-Picado, I Bravo, B Clotet.   Increased antiretroviral (ARV) potency by the addition of enfuvirtide (ENF) to a four drug regimen in ARV naïve HIV-infected patients.
2005	12th International Symposium on Hepatitis C and related viruses. Montreal, Canada, 13-19 Octubre 2005.
Franco S, Tural C, Clotet B and Martinez MA.   Complete genome sequence of two HCV genotype 4 variants isolated from two HIV-1 co-infected patients.
2005	4th General Meeting of the International Proteolysis Society.
Parera M, Clotet B and Martinez MA.   Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.
2005	6th International Workshop on HIV cells of Macrophage/ Dendritic lineage, and other reservoirs. Varenna, Italy. Oct. 05-07, 2005. Poster 11.
Izquierdo-Useros N, Blanco J, Fernández-Figueras MT, Erkizia-Jauregi I, Parrales P, Ruiz L, Clotet B, Martínez-Picado J.   Mature Monocyte Derived Dendritic Cells (mMDDCs) Capture and Transinfect Pseudotyped HIV-1 Independently of DC-SIGN
2005	Antivir Ther , 10 : 841-847
D Fuster , B Clotet , A Ballesteros , C Tural  Baseline factors predict haematological toxicity that lead to a dosage reduction of pegylated interferon alpha 2 and ribavirin in HIV and HCV coinfected patients on anti-HCV therapy
2005	ICAAC 2005,Washington 16-19 December 2005.
J Moltó, L Ruiz, M Valle, A Bonjoch, J Martinez Picado, I Bravo, B Clotet.   Increased antiretroviral (ARV) potency by the addition of enfuvirtide (ENF) to a four drug regimen in ARV naïve HIV-infected patients
2005	ICAAC, Washington 16-19 December 2005.
E. Negredo, J. Puig, A. Bonjoch, J. Moltó, A. Blanco, C. Rey-Joly, B.Clotet.   Ezetimibe, a Selective Inhibitor of Cholesterol Absorption, as a New Strategy for Treatment of Hypercholestero-lemia Secondary to Antiretroviral Therapy.
2005	ICAAC, Washington 16-19 December 2005. Poster session Presentation Number: H-527
Bonjoch A., Puig J., Miranda C., Erkizia I, Perez N., Puig T., Ruiz, L., Clotet B.   Discontinuation of enfuvirtide in HIV-infected patients on long lasting viral suppression.
2005	V Jornada de Virologia de Catalunya. Barcelona, November 2005
Franco S, Aparicio E, Clotet B i Martínez MA.   Sistema de cribat genètic per la caracterització de la ns3/ 4a proteasa de diferents genotips del virus de l’hepatitis C (VHC).
2005	VI International Workshop on HIV Cells of Macrophage Lineage and other Reservoirs. Varenna, Italy, Octubre 2005.
Berta Bosch, Imma Clotet-Codina, Julià Blanco, Gemma Comma, Samandhy Cedeño, Francesc Mitjans, Jaume Piulats, Margarita Bofill, Bonaventura Clotet, and Jose Este   Interference of Alpha-v Integrins Blocks HIV-1 Infection in Macrophages
2004	02. 11 st Conference on Retroviruses and Opportunistic Infections. ( Abstract 12) San Francisco, USA
R Draenert , T M Allen , G Sirera , C L Verrill , R Eldridge , L Ruiz , B D Walker, J Martínez Picado.  Comparison of CD8 T cell responses and viral escape in HIV-infected monozygotic twins.
2004	02. 11 st Conference on Retroviruses and Opportunistic Infections (Abstract 639) San Francisco, USA.
J G Prado , S Franco , T Matamoros , L Ruiz , B Clotet , L Menendez-Arias , M A Martínez , J Martínez Picado.   Replication capacity of multi-NRTI-resistant HIV-1 strains containing the insetion 69 and multiple amino acid changes in the RT.
2004	02. 11 st Conference on Retroviruses and Opportunistic Infections (Abstract 749) San Francisco, USA.
E Negredo , J Moltó , D Burger, P Viciana , E Ribera , J Puig , R Paredes , L Ruiz, A Pruvost, J Grassi , B Clotet.   Unexpected CD4 cell-count decline in patients receiving didanosine and Tenofovir based regimens despite undetectable viral load.
2004	02. 11st Conference on Retroviruses and Opportunistic Infections ( Abstract 802) San Francisco, USA.
M Gimenez-Barcons, A Llano , J A Esté , B Clotet , M A Martínez  GBV-C infection does not influence chemokine/cytokine expression patterns in HIV-1 infected patients.
2004	02. 11st Conference on Retroviruses and Opportunistic Infections (Abstract 718) San Francisco, USA.
R Murphy , C Katlama, G J Weverling , F Hoff, R Roubenoff , B Berzins , J Gatell , A Horban, A van Eeden, F Antunes, E Bijleveld , B Clotet , S Sataszewski, R van Leewen, J Lange, Atlantic Study Team.  Fat redistribution and metabolic study (FRAMS) in patients receiving a NRTI, NNRTI or PI based regimen over 4 years: FRAMS II substudy of the Atlantic Study.
2004	04. Keystone Symposium on HIV pathogenesis. Whistler , Canada.
J Barretina , A Bonjoch , J Blanco , A Llano , B Clotet , J A Esté.  Evaluation of HIV coreceptor expression in Enfuvirtide treated HIV patients
2004	04/01-04/04. VII European Conference on Psychological Assessment.
J A Muñoz-Moreno, C R Fumaz, M J Ferrer , A Tuldrà , B Clotet  Evaluación de déficits neuropsicológicos en la infección por VIH.
2004	04/01-04/04. VII European Conference on Psychological Assessment. Malaga, Spain
J A Muñoz-Moreno, C R Fumaz , M J Ferrer, A Tuldrà , B Clotet  Adhesión al tratamiento antiretroviral en la infección por VIH.
2004	04/01-04/04. VII European Conference on Psychological Assessment. Malaga, Spain
J A Muñoz-Moreno , C R Fumaz , M J Ferrer, A Tuldrà , B Clotet  Evaluación de la calidad de vida en la infección por VIH.
2004	05. 17th International Conference on Antiviral Research. Tucson, Arizona.
J A Esté , B Clotet  HIV drug - resistance to inhibitors of viral entry.
2004	05/25-05/28. XXX Congreso de la Sociedad Española de Inmunología. Santander, Spain.
R Ruiz-Hernandez, B Clotet , M Bofill  Patrones de expresión de quimiocinas que determinan la capacidad de migración de linfocitos T CD4+ y análisis de la expresión de CD31
2004	06/8-06/12. XIII International HIV Drug Resistance Workshop. Abstract 95 . Tenerife, Spain
C Gutierrez , C Mendoza , I Erkicia , M Leal, P Domingo , M J Pedreira , A Guelar , A Masabeu, J Iribarren , J L Blanco , J M Llibre , N Margall , S Pérez-Elias , S Gutierrez , J F Baldoví , X Camino , T Fumarola , S Moreno , B Clotet , V Soriano , L Ruiz on behalf of the Maratón TV3 Study Group.  Surveillance of HIV antiretroviral drug resistance and subtypes in newly diagnosed HIV-infected patients in Spain in 2003
2004	07/01-07/4. EUROMIT 6. Abstract P-1. Nijmegen, The Netherlands.
G Garrabou , S López , E Negredo , J Puig , E Sanjurjo , J Casademont , F Cardellach , B Clotet, O Miró.  Addition of tenofovir to a didanosine based highly active antiretroviral therapy increases mitochondrial toxicity.
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. MoOrB1058. Bangkok, Thailand
K Arastéh, A Lazzarin, B Clotet, J Lalezari, D Cooper, K Henry, M O'Hearn, J Reynes, P Piliero, B Trottier, J Montaner, S Walmsley, M Nelson, C Katlama, J Chung, R DeMasi, D Guimaraes, L Huson, L Donatacci, C Wat, T Kinchelow, A Bertasso, G D Miralles, M Salgo   TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. MoPeB3144. Bangkok, Thailand
J G Prado, A Shintani, N Izquierdo, M Bofill, B Clotet, L Ruiz, J Martinez-Picado  Evaluation of Boosted Signal Amplification of Heat-Dissociated p24 (H-Dp24 Ag)antigen detection in HIV-1 Chronic Infected patients during Structure Treatment Interruptions (STIs)
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeA4355. Bangkok, Thailand
M Parera, A Ibañez, B Clotet, M A Martinez   Lack of evidence for protease evolution in HIV-1 infected patients after two years on suppressive HAART
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeA4386. Bangkok, Thailand
N Tapia, M Parera, B Clotet, E Domingo, M A Martinez   Lethal mutagenesis as a new antiviral strategy
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4472. Bangkok, Thailand
J Barretina, J Blanco, A Bonjoch, A Llano, B Clotet, J A Este   Immunological and virological evolution of Enfuvirtide treated HIV patients
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4501. Bangkok, Thailand
M Johnson, L Nieto-Cisneros, A Horban, K Arasteh, J Gonzalez-Garcia, J Gatell Artigas, B Clotet, A Lazzarin, R Landman, S Proll, W Snowden, R Foreman, P Smith   Comparison of the gastrointestinal tolerability and patient preference for treatment with the Roche Nelfinavir 625 mg and 250 mg (Viracept®) tablet formulations
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4501. Bangkok, Thailand
J A Muñoz-Moreno, C R Fumaz, M J Ferrer, A Tuldrà, A Andreu, X Bonafont, B Clotet   Influence of the frequency in the medication collection on adherence to antiretroviral therapy of HIV+ patients
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4552. Bangkok, Thailand
H Gallais, A Lazzarin, A Adam, M Nelson, D Cooper, B Clotet, A Colebunders, J Lange, A Aguas, F Mulcahy, L Robertson, R Buffels, J Rooney   The Viread Expanded Access Program (EAP) in Europe/Australia: Summary of the Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral Treatment (ART) Experienced Patients
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4567. Bangkok, Thailand
L Ruiz, G Gómez, P Domingo, J Romeu, G Tambussi, J Martínez-Picado, C Miranda, J M Llibre, C Tural, G Sirera, F Vidal, C R Fumaz, E Negredo, B Clotet   A multicenter, randomized controlled clinical trial of continuous vs. intermittent HAART guided by CD4+ T cell counts and plasma HIV-1 RNA levels: two-year follow-up
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4568. Bangkok, Thailand
A Bonjoch, J Galvez, C Miralles, J de la Torre, A Prieto, C Vilades, M Marquez, A Mariño, D Peña, J Miranda, A Masabeu, J Pasquau, M Rubio, J A Terron, S Gel, M J Lopez, H Knobel, B Clotet   Trizivir™ or Combivir™ plus Nevirapine as a simplified strategies in HIV-1 infected patients with viral suppression. Results of 36 weeks of follow up of a randomized, multicenter open-label simplification trial. SimplifiHAART Study
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4586. Bangkok, Thailand
A Barrios, E Negredo, P Gil, T García-Benayas, B Clotet, V Soriano   Pardoxical CD4+ T cell decline in patients with complete virus suppression under tenofovir plus didanosine combinations
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4589. Bangkok, Thailand
J Molto, E Negredo, J Romeu, G Sirera, C Tural, J Puig, J Miranda, B Clotet   Efficacy and tolerance after two years of a PI-sparing simplification approach in HIV-infected adults with long-lasting viral suppression
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. TuPeB4602. Bangkok, Thailand
J A Muñoz-Moreno, C R Fumaz, E Negredo, J Moltó, S Gel, J Puig, E Martínez, M J Ferrer, B Clotet   Impact of a once-daily antiretroviral regimen on quality of life and adherence to treatment of HIV infected patients with viral load suppression
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WeOrB1326. Bangkok, Thailand
C Tural, G Gómez, M A Martínez, N Pérez, D Fuster, A L Ballesteros, G Sirera, L Ruíz, R Schuurman, C Rey-Joly, R Planas, B Clotet   Impact of highly active antiretroviral therapy interruption strategies in plasma hepatitis C virus kinetics in human immunodeficiency and hepatitis C virus co-infected patients
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeA5653. Bangkok, Thailand
I Clotet-Codina, M Armand-Ugon, B Clotet, J A Este   Mapping of polyanion drug -resistance to a single amino acid of the gp120 of human immunodeficiency virus type 1
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeA5658. Bangkok, Thailand
M Armand-Ugon, I Clotet, S Jiang, B Clotet, J A Este   HIV-1 resistance to ADS-J1
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeA5661. Bangkok, Thailand
J Martinez-Picado, J G Prado, N Izquierdo, L Ruiz, B Clotet   Implications of accumulation of drug resistant mutations in pol and gag genes during Treatment in HIV-1 infected patients with sustained CD4 count despite a virologic rebound
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5687. Bangkok, Thailand
E Fernandez-Cruz, J Navarro, M L Abad, L Diaz, C Rodriguez-Sainz, J Carbone, S Moreno, J Perez-Molina, J M Peña, D Podzamczer, I Ocaña, B Clotet, R Rubio, F Pulido, P Viciana, J A Maradona, R Blazquez, C Barros, C Quereda, M Diaz, J M Gatell, M A Muñoz-Fernandez, J Gil, J Gonzalez-Lahoz, F Garcia-Sanchez, J L Vicario, M Clerici   Therapeutic immunization with an HIV-1 immunogen (REMUNE) induces HIV-1-specific responses against HIV-1 antigens and alloresponses against HLA-alloantigens
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5844. Bangkok, Thailand
J A Muñoz-Moreno, A Tuldrà, C R Fumaz, M J Ferrer, N Pérez-Álvarez, N Garrido, B Clotet   Predictive models for adherence to antiretroviral treatment in HIV infected patients
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5896. Bangkok, Thailand
O Miro, E Negredo, S Lopez, L Ruiz, G Garrabou, E Sanjurjo, J Casademont, F Cardellach, B Clotet   Mitochondrial effects of adding tenofovir to a HAART regimen containing didanosine
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5926. Bangkok, Thailand
E Negredo, J C Martinez, C R Fumaz, E Martinez, C Higueras, X Adell, J A Muñoz-Moreno, V Gonzalez-Mestre, B Clotet   Open pilot clinical trial to evaluate the efficacy of reparatory treatment in facial lipoatrophy secondary to antiretroviral treatment.
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5930. Bangkok, Thailand
C R Fumaz, J A Muñoz-Moreno, M J Ferrer, E Negredo, J C Martínez, E Martínez, X Adell, C Higueras, V P González Mestre, B Clotet   Psychological assessment of HIV-infected patients with facial lipoatrophy before and after reparatory treatment
2004	07/11-07/16 The XV International AIDS Conference, Abstract no. WePeB5935. Bangkok, Thailand
C R Fumaz, J A Muñoz-Moreno, M J Ferrer, G Sirera, J Moltó, N Pérez, D M Burger, B Clotet   Efavirenz after two years of treatment: Tolerability, quality of life and adherence
2004	07/18-07/23. 12th International Congress of Immunology and 4th Annual Conference of Foci. Montreal, Canada.
M Bofill , R Peña , R Ruiz-Hernandez , M Naranjo , B Clotet , F E Borràs.  The cytokine receptors for human IL-12 and IL-18 are preferentially expressed on effector memory lymphocytes.
2004	10. 44 ICAAC. Washington , USA.
E Negredo, J Puig, E Masmitjà , J Moltó, L Ruiz , B Clotet  CD4 cell count changes after reduction of didanosine dosage in patients receiving didanosine and tenofovir based regimens.
2004	10/25-10/28. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Abstract 26.Washington, USA.
G Garrabou, S López , A B Infante , E Negredo , J Puig , L Ruiz , E Sanjurjo , J Casademont , F Cardellach , B Clotet and O Miro  Adddition of tenofovir to a didanosine-based HAART does not increase mitochondrial DNA depletion but decreases cytochrome c oxidase function and mitochondrial mass.
2004	11/14-11/17. 7th International HIV Conference. Glasgow, Scotland
E Negredo , A Bonjoch , R Paredes , B Clotet  Current administration of tenofovir (TDF) and Didanosine (ddl) compromises immunologic recovery in treatment-experienced patients. Results from the TORO studies. (P 3)
2004	11/14-11/17. 7th International HIV Conference. Glasgow, Scotland.
G Garrabou , S López , A B Infante , E Negredo , J Puig , L Ruiz , E Sanjurjo , J Casademont , F Cardellach, B Clotet , O Miro  Addition of tenofovir to a didanosine-based HAART does not increase mitochondrial DNA depletion but decreases cytochrome c oxidase function and mitochondrial mass
2004	12/07-12/10. Annual congress of the British Society for Immunology. Harrogate, England
R Ruiz - Hernandez , B Clotet , M Bofill  Differential expression of chemokines receptors on CD31+ naive and memory CD4T cells.
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 183). Boston, USA
Jan van Lunzen, B Zöllner, HJ Stellbrink, C Schneider, O Degen, S Staszewski, S Christensen, L Ruiz, B Clotet, K Tenner-Racz, P Racz  How Hard Is HAART? Residual Viral Replication and Evolution in Lymphoid Tissue during Sustained Control of Viremia
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 221). Boston, USA
MA Martinez, A Gutierrez, M Armand-Ugon, J Blanco, M Parera, J Gomez, B Clotet, J.A. Este  RNA Interference of Chemokine Receptor Expression Allows for Inhibition of HIV-1 Replication
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 291). Boston, USA
J Blanco*, J Barretina, B Clotet, J A Esté  Massive Transfer of HIV Particles to Non-permissive Cells during Cell-to-Cell Contacts
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 558). Boston, USA
S. Walmsley*1, K. Henry2, C. Katlama3, M. Nelson4, A. Lazzarin5, J. Reynes6, B. Clotet7, M. Salgo8, R. Demasi9, J. Delehanty  Lack of Influence of gp41 Antibodies that Cross-react with Enfuvirtide on the Efficacy and Safety of Enfuvirtide in TORO 1 and TORO 2 Phase III Trials
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 641). Boston, USA
E. Fernandez-Cruz, J. Navarro, S. Moreno, J. Pérez Molina, M. L. Abad, L. Díaz, C. Rodriguez Sainz, J. M. Peña, D. Podzamczer, I. Ocaña, B. Clotet, M. A. Muñoz-Fernandez, J. Gil, J. Carbone, J. Gonzalez-Lahoz  Therapeutic Vaccination Induce Strong and Long-lasting HIV-specific Cellular Immunological Responses in ART-naïve and ART-experienced HIV-1+ Individuals
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 65). Boston, USA
L. Ruiz, L. Gómez, P. Domingo, J. Romeu, G. Tambussi, J. Martínez-Picado, J. Miranda, J. C. Martínez, J. M. Llibre, C. Tural, G. Sirera, F. Vidal, CR. Fumaz, E. Negredo, B. Clotet  A Multi-center, Randomized Controlled Clinical Trial of Continuous vs Intermittent HAART Guided by CD4+ T-cell Counts and Plasma HIV-1 RNA Levels
2003	02/10-02/14 10th Conference on Retroviruses and Opprtunistic Infections. (Abstract 845). Boston, USA
M. A. Martinez, B. Clotet  A Genetic Screen to Monitor the Activity of the Hepatitis C Virus NS3 Serine Protease
2003	03/29-04/04. Twenty Years of HIV Research., Keynstone Symposia. Keynstone, USA.
M Bofill , R peña , L Ruiz , B Clotet  Immune reconstitution of CD4+CXCR5+ T helper follicular cell in HIV infection
2003	04. 17th ICAR. Savanah, Georgia.
J A Esté , M A Martínez , A Gutierrez , M Parera , M Armand-Ugon , J Blanco , B Clotet  Suppression of chemokine receptor expression by RNA interference (RNAi) allows for inhibition of HIV-1 replication.
2003	04. Keystone Symposium on HIV patogenesis. Banff , Canada
A Llano , J Barretina , A Gutierrez , B Clotet , J A Esté  Interleukin-7 dependent production of RANTES that correlates with HIV disease progression
2003	04. Keystone Symposium on HIV Pathogenesis. Whistler, Canada
J Barretina , A Bonjoch , J Blanco , A Llano , B Clotet , J A Esté  Evaluation of HIV coreceptor expression in Enfurvitide treated HIV patients
2003	04/12-04/16. The 3rd International Meeting of the Edward Jenner Institute for Vaccine Research. Oxford, USA
M Bofill , R Peña , L Ruiz , B Clotet  Immune reconstitution of CD4+CXCR5+ T helper follicular cell in HIV infection
2003	05/07-05/09. SEISIDA. Bilbao, Spain
A Gutierrez , M A Martinez , M Armand-Ugon, J Blanco , N Tapia , M Parera , B clotet , J A Esté  Inhibición de la entrada y replicación del VIH por interferencia de RNA (RNAi) de los receptores de quimiocinas.
2003	05/20-05/23. Retrovirus, Cold Spring Harbor. USA
G Fernández , B Clotet , M A Martínez  High-resolution structure of HIV-1 protease quasispecies.
2003	05/29-05/30. XXLX Congreso de la Sociedad Española de Inmunología. Cadiz , Spain
M Naranjo , R Peña , F E Borras , M Bofill  Expresión diferencial del receptor de IL-12 en linfocitos T derivados de sangre de cordón umbilical.
2003	06/10-06/14..XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Abstract 24. Los Cabos, México
M Armand-Ugón, A Gutiérrez, S Jiang, B Clotet and JA Esté  ADS-J1, a non-peptidic low molecular weight HIV fusion inhibitor targeting gp41, with no cross-drug resistance with peptidic HIV fusion inhibitors T-20 and C-34, and HIV binding inhibitors (Abstract 24)
2003	06/10-06/14..XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Abstract 90 . Los Cabos, México
K Morales-Lopetegi, C Gutierrez, N Izquierdo, S Marfil, B Clotet, L Ruiz and J Martínez-Picado  Evidence for preferential genotyping of minority HIV populations due to primer mismatching during PCR-based amplification (Abstract 90)
2003	09/14-09/17. 43rd ICAAC (Abstract H-1945) Chicago, USA
J Barretina Ginesta , J Blanco , A Gutierrez , B Clotet , J A Esté  Extended Lymphocyte survival induced by HIV-1 gp 120
2003	The 2nd IAS Conference on HIV Pathogenesis and Treatment
J Martínez-Picado, E Negredo, L Ruiz, A Shintani, CR Fumaz, C Zala, P Domingo, J Vilaró, JM Llibre, P Viciana, K Hertogs, C Boucher, RT D'Aquila, B Clotet, and the SWATCH Study Team  Alternation of Antiretroviral Drug Regimens for HIV Infection: A Randomized, Controlled Trial (Late Breaker 05)
2003	The 2nd IAS Conference on HIV Pathogenesis and Treatment
J Blanco, B Clotet, JA Este
2002	02/23 - 02/28 . 9th Conference on Retroviruses and Opportunistic Infections ( Abstract 415-W). Chicago, USA.
S Follansbee , J Reynes , M Nelson , B Clotet , A Lazzarin , A Adam , S Van Doren , R Buffels , S Barriere , L Zagury , I Miranki , J Ronney.  The Viread expanded access program : safety and efficacy of tenofovir disoproxil fumarate in antiretroviral treatment experienced patients.
2002	02/23 - 02/28 . Conference on Retroviruses and Opportunistic Infections (Abstract 646 - M) Chicago, USA.
D Fuster , C Tural , J Tor , J Romeu , I Ojanguren , G Sirera , R Muga , A Ballesteros , E Negredo , H Guardiola , R Planas , C Rey-Joly , B Clotet  Factors associated with liver fibrosis in HIV-1 HCV co-infected patients on antiretroviral therapy.
2002	02/23 - 02/28. 9th Conference on Retroviruses and Opportunistic Infections ( Abstract 421W) Chicago, USA
L Ruiz , E Ribera , A Bonjoch , J Martinez-Picado , M Díaz , J Romeu , S Marfil , E Negredo , J García-Prado , C Tural , T Puig , G Sirera , B Clotet.  Virological and Immunological Benefit of a Salvage Therapy that Includes Kaletra plus Fortovase Preceded or not by Antiretroviral Therapy Interruption (TI) in Advanced HIV-Infected Patients (6-Month-Follow-up)
2002	02/23 - 02/28. 9th Conference on Retroviruses and Opportunistic Infections (Abstract 50) Chicago, USA
J. Martinez-Picado, S D W Frost, S Marfil, T Puig, B Clotet, L Ruiz  Viral Populations Emerging in Plasma during Sequential Structured Treatment Interruptions in Chronically HIV-Infected Individuals Are Genetically Distinct between Time-Points and Tissues
2002	02/23 -02/28 . 9th Conference on Retroviruses and Opportunistic Infections (Abstract 318 W) Chicago, USA.
E Fernandez-Cruz , J Navarro , M L Abad , L Diaz , C Cantó , J Carbone , S Moreno , B Clotet , J Perez Molina , J M Gatell , M A Muñoz-Fdez , Spanish 2102 Team.  Augmentation of HIV-1 specific memory subsets of T Lymphocytes and decrease of inmune activation in HIV1+ individuals treated with a therapeutic vaccine plus antiretrovirals : Impact on viral load.
2002	02/23- 02/28 . 9th Conference on Retroviruses and Opportunistic Infections (Abstract 707T) Chicago, USA.
H Côté , E Negredo , L Ruiz , S Langridge , Z Brumme , J Martínez-Picado , M O’Shaughnessy , P R Harrigan , B Clotet , J Montaner  Antiretroviral Regimen-Dependent Mitochondrial DNA Depletion in Clinical Samples from the SWATCH Trial
2002	02/23-02/28 . 9th Conference on Retroviruses and Opportunistic Infections (Abstract 181M) Chicago, USA
J. Blanco , J Barretina , B Clotet , J A Esté  Gp41-Mediated Apoptosis is Independent of HIV Co-Receptor Use but Requires Proper Presentation by gp120.
2002	03. 15th International Conference on Antiviral Research (ICAR) Pague.
J A Esté , J blanco , J Barrtetina , B clotet  Inhibition of HIV fusion
2002	03. SEISIDA. Caceres, SPain
M Armand-Ugon , A Gutierrez , J Barretina , B Clotet , J A Esté  HIV resistance to gp41 dependent fusion inhibitors
2002	04. Keystone Symposium on HIV pathogenesis. Keystone , USA.
A Llano , J Barretina , A Gutierrez , B Clotet , J A Esté.  Interleukin/ promotes X4 HIV entry by increasing CXCR4 and B-chemokine levels.
2002	07/02 - 07/05 . XI International HIV Drug Resistance Workshop (Abstract 111) Sevilla, Spain
M E Quiñones-Mateu , J Weber , H R Rangel , B Chakraborty , M A Martínez , J A esté , J Martínez-Picado , L Ruiz , B Clotet , T Wrin , C Petropoulos.  A novel Taqman Real-Time PCR meted to estimate HIV-1 fitness in the era of multi-target antiretroviral therapy.
2002	07/02 - 07/05 . XI International HIV Drug Resistance Workshop (Abstract 13) Sevilla, Spain.
S D Kemp , L Ruiz , A M Lucas , A Bonjoch , J Martínez Picado , B A Larder , B Clotet  Novel mutations in a highly conserved region of HIV-1 gp41 are associated with T-20 treatment.
2002	07/02 - 07/05 . XI International HIV Drug Resistance Workshop. (Abstract 154) Sevilla, Spain
L Ruiz , E Ribera , A Bonjoch , J Martínez-Picado , M Diaz , J Romeu , S Marfil , E Negredo , J García-Prado , C Tural , T Puig , G Sirera , B Clotet.  Virological and immunological benefit of a salvage therapy that includes Kaletra+Fortovase preceded or not by antiretroviral therapy interruption in advanced HIV-infected patients (48 weeks follow-up)
2002	07/02-07/05 . XI International HIV Drug Resistance Workshop (Abstract 81) Sevilla, Spain
J Van Lunzen , B Zöllner , H J Stellbrink , I Stahmer , C Shneider , L Ruiz , B Clotet , P Racz , Tenner-Racz  Development of viral quasispecies and resistance mutations in lymph nodes of HIV-infected patients with sustained control of viraemia during highly active antiretroviral therapy
2002	07/02-07/05. XI International HIV Drug Resistance Workshop (Abstract 13) Sevilla, Spain
M Armand Ugon, A Gutierrez , B Clotet , J A Esté  HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
2002	07/07 - 07/12 . XIV International AIDS Conference (Abstract TuPeB4609) Barcelona, Spain
C L Reid , D L Winslow , K Smith , J D Baxter , F Brun-Vezinet , B Clotet , R M Grant , C Loveday , T C Merigan , W O'Brian , M A Wainberg , J M Schapiro.  HIV-1 drug resistance genotype interpretation: how to establish and maintain an algorithm.
2002	07/07 - 07/12 . XIV International AIDS Conference (Abstract WePeB5831) Barcelona , Spain
A Tuldra , C R Fumaz , M J Ferrer , R Bayes , A Ballesteros , A Bonjoch , A Jou , E Negredo , J Romeu , G Sirera , C Tural , B Clotet.  Factors related to adherence to HAART in patients in usual clinical follow-up
2002	07/07 - 07/12 . XIV International AIDS Conference (Abstract WePeB5834) Barcelona ,Spain
C R Fumaz , A Tuldra , M J Ferrer , M Barceló , E Negredo , S Gel , E R Arisa , B Clotet.  Impact of a once-daily three drug antiretroviral regimen on the quality of life and adherence of HIV-1+ patients with viral load supresión.
2002	07/07 - 07/12 . XIV International AIDS conference (ABSTRACT WePeB5985) Barcelona, Spain
J C Lopez , E Bouza , P Domingo , B Clotet , H Knobel , L F L Cortes , J M Gatell , J Sanz , E Fernández-Cruz.  Baseline characteristics of patients enrolled in ESPRIT
2002	07/07- 07/12 . XIV International AIDS Conference (Abstract TuPeB4526) Barcelona, Spain
E Negredo , G Sirera , J Puig , C R Fumaz , S Gel , B Clotet  Management of nelfinavir-related diarrhoea
2002	07/07-07/12 . XIV International AIDS Conference (Abstract TuPeA4395) Barcelona ,Spain
N Tapia , B Clotet , M A Martínez  A bacteriophage lambda-based screening system for the characterization of the activity and phenotype of HIV-2 protease
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT A10012) Barcelona,Spain
J Blanco , J Barretina , B Clotet , J A Este  HIV Envelope-induced cell death requires coreceptor expresión and gp41 function.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT A10035) Barcelona,Spain
G Fernandez , B Clotet , M A Martínez  High-resolution structure of HIV-1 protease quasispecies
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT A10128) Barcelona,Spain
C Tural , D Fuster , A Ballesteros , C Alcalde , R Guerola , G Sirera , J Romeu , E Negredo , J Tor , C Rey-Joly , L Ruiz , B Clotet  Efficacy of regimens containing Lopinavir/Ritonavir (kaletra) in highly portease inhibitor-experienced HIV + patients . Six months follow-up.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT B10379) Barcelona,Spain
G Sirera , M Millan , I Ojanguren , C Tural , J Romeu , E Negredo , A Ballesteros , B Clotet , J Coll  Pharingeal myopathy presentation of mitochondrial myopathy in HIV patient treated with nucleoside analogues.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT B10382) Barcelona,Spain
S Johnston , E R Arisa , S Gel , E Negredo , G Sirera , A Bonjoch , A Tuldra , J Romeu , B Clotet  Evaluation of changes in body composition and metabolic parameters in HIV + patients initiating antiretroviral treatment.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT B10384) Barcelona,Spain
A Ballesteros , C Tural , A Salas , B Clotet.  Incidence of peripheral neuropathy associated to pegilated-interferon, in coinfected HVC/HIV
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT B10438) Barcelona,Spain
A Tuldrà , C Fumaz , M J Ferrer, R Bayes , T Rovira , C Viladrich , I Izquierdo , M Barceló , G Sirera , E Negredo , J Romeu , B Clotet  Preliminary validation of a questionnaire to assess self-reported adherence to HAART.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT ThOrA1482) Barcelona,Spain
E Fernández-Cruz , J Navarro , M L Abad , L Diaz , C Canto-Nogues , M C Rodríguez Sainz , J Carbone , M A Muñoz-Fernandez , S Moreno , J Perez-Molina , B Clotet , J M Gatell , D Podzamczer , J Gonzalez-Lahoz.  3 year evaluation of a therapeutic vaccine (HIV_1 Immunogen) administred with antiretrovirals versus antiretroviral therapy alone in patients with HIV chronic infection.
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT ThPeC7495) Barcelona,Spain
D Fuster , C Tural , H Guardiola , J Tor , J Romeu , G Sirera , R Muga , A Ballesteros , R Planas , C Rey-Joly , B Clotet  Clinical profile of HIV positive patients with end stage liver disease attending an outpatient AIDS clinical Unit at a University Hospital
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT ThPpB2135) Barcelona,Spain
C R Fumaz , A Tuldra , M J Ferrer , M Barcelo , J Miranda , J C Martínez , L Ruiz , B Clotet.  Quality of life and emotional status of HIV+1+ patients with viral load supressión in structured treatment interruptions
2002	07/07-07/12 . XIV International AIDS Conference. (ABSTRACT WePeB6045) Barcelona,Spain
A Ballesteros , C Tural , D Fuster , R Planas , H Guardiola , G Sirera , J Romeu , A Salas , S Johnston , J Tor , C Rey-Joly , R Muga , B Clotet  Haematological toxicity, effect on CD4 cell count and on body mass index (BMI) of combined treatment with Peg-Intron (1,5 ug/kg/week)+ribavirin (400 mg/bid) for hepatitis C virus (HCV) infection in HIV+patients on antiretroviral therapy (ART)
2002	07/07-07/12. XIV International AIDS Conference (Abstract ThPeC7118) Barcelona , Spain
R Draener , L Ruiz , B Clotet , B D Walker , J Martínez-Picado  Differential Cd8 T cell responses to HIV-1 in infected monocygotic twins
2002	07/07-07/12. XIV International AIDS Conference (Abstract TuPeB4468) Barcelona, Spain
M Nelson , B Clotet , C Katlama , S Follansbee , D Cooper , A Adam , A Lazzarin , J Montaner , J Lange , S Van Doren , R Buffels , G Ghoy , L Zagury , J Rooney.  The Viread global expanded access program (EAP); safety and efficacy of tenofovir disoproxil fumarate (TDF) in antiretroviral treatment (ART) experienced patients
2002	07/07-07/12. XIV International AIDS Conference (Abstract TuPeB4518)Barcelona, Spain
E Negredo , R Guerola , J Miranda , E R Arisa , A Jou , C Tural , A Ballesteros , G Sirera , A Bonjoch , J Romeu , B Clotet  Impact of pravastatin on dyslipidemia induced by antiretroviral therapy
2002	07/07-07/12. XIV International AIDS Conference (Abstract TuPeF5370) Barcelona, Spain
A M J Wensing , J Albert , C Balotta , R Camacho , B Clotet , B Fleckentein , W may , A Hatzakis , C Holm-Hansen , A Horban , C Loveday , C Nielsen , E Puchhammer-Stockl , M Salminen, J C Schmit , R Schuurman , A M Vandamme , C A B Boucher.  Systematic surveillance of transmission of HIV resistance in Europe : The Spread Project.
2002	07/07-07/12. XIV International AIDS Conference (Abstract WePeA5723) Barcelona, Spain.
M A Martínez , M Parera , B Clotet  Protease diversity changes in HIV-1 infected individuals receiving highly active antiretroviral.
2002	07/07-07/12. XIV International AIDS Conference. (Abstract TuOrA1135) Barcelona, Spain
A Llano , J Barretina , A Gutierrez , B Clotet , J A Esté  Interleukin-7 accelerates HIV X4 replication by inducing the production of B-chemokines, downregulation of CCR5 and upregulation of CVCR4
2002	07/30. XII International Congress of Virology . Paris, France
M A Martínez , B Clotet  A genetic screen for the characterization of the activity of the Hepatitis C Virus NS3 serine protease.
2002	070/07 - 07/12. XIV International AIDS Conference (Abstract WePeA5728) Barcelona, Spain
M Armand-Ugon , M Quinones-Mateu, A Gutierrez , J Barretina , J Blanco , D Schols , E de Clercq , B Clotet , J A Esté.  Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
2002	09/02-09/06. 8th European Workshopon virus evolution and molecular epidemiology. Leuven, Belgica
G Fernandez , B Clotet , M A Martínez  High-resolution structure of HIV-1 protease quasispecies.
2002	09/27-09/30 . 42nd ICAAC (Abstract H-173) San Diego, California
P Viciana , E Redondo , S Moreno , B Clotet , FÉNIX Study Group.  A multicenter, open label, 24 week study of Indinavir (IDV) 800 mg and ritonavir (RTV) 200 mg bid plus 2 NRTIs in Heavily pretreated HIV-1 infected patients (the FENIX study)
2002	09/27-09/30 . 42nd ICAAC (Abstract H-1918) San Diego , California
E Negredo , J Ribalta , E Arisa , G Sirera , C Tural , J Romeu , A Bonjoch , A Jou , A Ballesteros , L Masana , B Clotet  Efavirenz, lipid metabolism and cardiovascular risk.
2002	09/27-09/30. 42nd ICAAC (Abstract H-1144) San Diego, California
H Guardiola , J Tor , C Tural , D Fuster , S Santaeugènia , G Sirera , J Romeu , C Rey-Joly , B Clotet  AIDS-related hospital morbidity and mortality in the HAART era (1997-2001)
2002	09/27-09/30. 42nd ICAAC (Abstract H-1728) San Diego , California.
C R Fumaz , M Barcelo , J Romeu , A Tuldra , M Ferrer , A Ballesteros , A Salas , C Tural , B Clotet  Depresión and quality of life in HIV-1 + patients with chronic hepatitis C virus infection treated with interferon and ribavirin.
2002	09/27-09/30. Bisphosphonate and osteoroporosis in HIV infected patients. A pilot study (Abstract V-685). San Diego, California.
A Ballesteros , C Tural , E Arisa , C R Fumaz , G Sirera , D Fuster , C Rey-Joly , J Tor , B Clotet.  Safety of peg-interferon (Peg-IFN) & Ribavirin (RBV) for chronic hepatitis c (HCV) in HIV-infected patients.
2002	12/03-12/06 . British Society of Immunology Congress. Harrogate
R Peña , L Ruiz , B Clotet , M Bofill  Helper follicular CD4+ CXCR5+ T cells are not preferentially target by HIV-1
2001	02/04-02/08. 8th. Conf. on Retroviruses and Opportunistics Infections. (Abstracts 324) Chicago , USA
A N Philips, C Pradier , A Lazzarin , B Clotet , F Goebel , P Hermans , F Antunes , B Ledergerber , O Kirk , J Lundgren  Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA.
2001	02/04-02/08. 8th. Conference on Retroviruses and Opportunistics Infections. (Abstracts 117 ) Chicago , USA
J Blanco , J Barretina , A Gutierrez , C Cabrera , B Clotet , J A Esté  HIV.-1 Envelope transmembrane subunit (gp41) is required for envelope-induced apoptosis in single uningected CD4+ T Cells.
2001	02/04-02/08. 8th. Conference on Retroviruses and Opportunistics Infections. (Abstracts 291 ) Chicago , USA
L Ruiz , G Carcelain , J Martínez-Picado , S Frost , S Marfil , R Paredes , J Romeu , K Morales-Lopetegi , B Autran , B Clotet  HIV Dynamics and HIV-Specific CD8+T cells response after three structured treatment interruptions (STI) of antiretroviral treatment (ART) in chronic HIV-infected patients.
2001	02/04-02/08. 8th. Conference on Retroviruses and Opportunistics Infections. (Abstracts 654B ) Chicago , USA
M Van der Valk , P Reiss , H Molhuizen , R Stellato , C Katlama , A Horban , M Glesby , G Behrens , B Clotet , J Kastelein , R Murphy on behalf of the Atlantic investigators.  Nevirapine containing potent antiretrovial therapy results in ananti-atherogenic plasma lipid profile: results from the Atlantic trial.
2001	02/04-02/08. 8th. Conference on Retroviruses and Opportunistics Infections. (Abstracts 668 ) Chicago , USA
E Martinez , J Romeu , M A García Viejo , L Cruz , J L Blanco , E Negredo , B Clotet , J M Gatell   An open randomized study on the replacement of HIV-1 protease inhibitors by Efavirenz in Chronically suppressed HIV-1 infected patients with Lipodystrophy.
2001	02/04-08/04. 8th. Conference on Retroviruses and Opportunistics Infections. (Abstract 669) Chicago, USA
E Negredo , J Martinez Picado , L Ruiz , C Zala , K Hertogs , C Boucher , R D'Aquila , B Clotet  SWATCH study: A multicenter trial of proactive treatment switching. Results at 9 months follow-up.
2001	02/15-02/17. SENBA . Palma de Mallorca, Spain
S Johnston , E R Arisa , S Gel , E Negredo , A Bonjoch , B Clotet  Correlación entre tres métodos para determinar la composición corporal (CC) en pacientes VIH+ que inician tratamiento antiretroviral
2001	02/19. Biology of Chemokines in Disease. Keynstone Simposium (Abstract 330) Keystone, USA
A Llano , A Gutiérrez , J Blanco , J Barretina , C Cabrera , B Clotet, J A Esté.  High contentrations of SDF-1 in plasma modulate the expression of CXCR4 in vivo and preferently select the human immunodeficiency virus-1 (HIV-1) non syncytium inducing phenotype (NSI).
2001	02/23-02/25. 3rd. European Symposium on the Clinical Implications of HIV Drug Resistance. (Abstract 66) Frankfurt , Germany
O Gallego Donoso , L Ruiz , A Vallejo, E Ferrer , B Clotet , M Leal , V Soriano, the ERASE-3 Group.  Changes in the rate of genotyoic resístanse to antirretrovirals drugs in Spain.
2001	02/23-02/25. 3rd. European Symposium on the Clinical Implications of HIV Drug Resistance.(Abstract 34) Frankfurt, Germany
C Tural , L Ruiz , C Holtzer , P Viciana , J González , E Ferrer , J Martínez-Picado , I Ruiz , D Dalmau , P Domingo , A Been , G Sirera , B Clotet , Havana Study Group  Utility of HIV genotyping and clinical expert advice – the Havana Trial.
2001	03/31 . HIV Pathogenesis. Keystone Symposium (Abstract 301) Keystone, USA
J Barretina , J Blanco , A Llano , A Gutierrez , C Cabrera , B Clotet , J A Esté  Death of CD8+T cell during human immunodeficiency virus infection correlates to viral load but is independent of viral phenotype.
2001	03/31. HIV Pathogenesis. Keystone Symposium. (Abstract 308) Keystone, USA.
J A Esté , A Llano , J Blanco , J Barretina , A Gutierrez , B Clotet.  Stromall-cell derived factor 1 and interleukin-7 as markers for the emergence of syncytium inducing strains fo human immunodeficiency virus 1 and disease progression.
2001	04. Keystone Symposium on Chemokines. New Mexico
A Llano , J Barretina , J Blanco , A Gutierrez , B Clotet , J A Esté  High concentrations of SDF-1 in plasma modulate the expression of CXCR4 in vivo and preferently select the HIV-1 non syncytium inducing phenotype.
2001	04/01-04/04 .11th. European Congress of Clinical Microbiology and Infectious Diseases. Istambul , Turkey
C Muñoz, C Fortuny, A González Cuevas, B Clotet, L Ruiz, C Latorre.  Genotipic mutations associated with antiretroviral drug resistance in HIV-1 infected children by vertical transmission.
2001	04/03 - 04/06 . VI Congreso Nacional sobre el SIDA. (Abstract CPO6p2) Valencia , Spain
S Gel , S Johnston , E R Arisa , E Negredo , B Clotet  Estudio de la redistribución de la grasa corporal en pacientes infectados por VIH que inician distintas estrategias de tratamiento antiretroviral (subestudio SWATCH)
2001	04/03-04/06 . VI Congreso Nacional sobre el SIDA (Abstract CPO18pl) Valencia , Spain
C R Fumaz , A Tuldrà , M J Ferrer , E Negredo , S Gel , A Bonjonch , L Ruiz , B Clotet  Calidad de vida y principales preocupaciones asociadas al síndrome de lipodistrofia en pacientes VIH+1 con supresión viral a largo plazo.
2001	04/03-04/06. VI Congreso Nacional sobre el SIDA (Abstract MR14p4) Valencia , Spain
A Llano , J Barretina , A Gutierrez , J Blanco , B Clotet , J A Esté  Asociación de la aparición del fenotipo inductor de sincitios del VIH-1 con los niveles de SDF-1 e IL-7 en plama.
2001	04/03-04/06. VI Congreso Nacional sobre el SIDA (Abstract CP010p2) Valencia, Spain
N Tapia , S Franco , F Puig-basagoiti , C Menéndez , B Clotet , J C Saiz , M A Martínez.  Transmisión vertical de diferentes subtipos del virus de la inmunodeficiencia humana de tipo 1.
2001	04/03-04/06. VI Congreso Nacional sobre el SIDA (Abstract MR2p3) Valencia, Spain
A Gutierrez , M E Quiñones Mateu , A Llano , J Blanco , J Barretina , B Clotet , J A Esté   Disminución de la capacidad replicativa (fitness) de VIH-1 resistentes a compuestos antagonistas de CXCR4.
2001	04/03-06/03 .VI Congreso Nacional sobre el SIDA (Abstract CP10p2) Valencia, Spain
A Gutierrez , J Blanco , A Llano , J Barretina , B Clotet , J A Esté  Utilización de la PCR cuantitativa para el screening de nuevos compuestos con actividad anti-vih en las etapas tempranas de la replicación viral.
2001	04/08- 04/12 .14th. International Conference on Antiviral research. Seattle, USA
J A Esté , C Cabrera , J Barretina , A Gutierrez , A Litovchick , A Lapidot , B Clotet  Anti-HIV activity of a neumycin B-arginine conjugate.
2001	04/13-04/16. 5º Congreso Nacional sobre el SIDA (Abstract CP8-7) Santiago de Compostela , Spain
R Paredes , T Puig , A Arnó , M Balagué , A Bonjoch , A Tuldrá , A Veny , J Romeu , L Ruiz , B Clotet  Los tratamientos de rescate altamente activos que incluyen ritonavir y altas dosis de saquinavir son efectivos a largo término en pacientes VIH+ que fracasan a terapias iniciales que incluyen saquinavir , indinavir o ritonavir
2001	04/19-04/21. 4th International Conference on Nutrition and HIV infection. 2nd European Workshop on lipodystrophy . Cannes , France
S Gel , S Johnston , E R Arisa , E Negredo , A Bonjoch , B Clotet  Body fat redistribution in HIV-1 infected patients after initiatind antiretroviral treatment
2001	04/19-04/21. 4th International Conference on Nutrition and HIV infection. 2nd European Workshop on lipodystrophy . Cannes , France
S Johnston , E R Arisa , S Gel , E Negredo , A Bonjoch , B Clotet  Nutritional status of HIV-1 + naïve patients
2001	05/23-05/25. XVII SENPE. Granada, Spain
S Johnston , E R Arisa , S Gel , E Negredo , A Bonjoch , B Clotet  Situación nutricional actual del paciente infectado por VIH-1+
2001	05/30-06/01. XXVII Congreso Nacional de la Sociedad Española de Reumatología. Madrid , Spain
M Valls , V Ortiz-Santamaria , A Olivé , M Cervantes , J Gratacós , G Sirera , C Tural , E Negredo , X Tena , B Clotet  Ostenecrosis aséptica e infección por el VIH
2001	06. European Conference on Experimental AIDS Research. Edinburgh , UK
J Barretina , J Blanco , M Armand-Ugon , A Gutierrez , B Clotet , J A Esté  The fusion inhibitor C34 exerts his anti-HIV activity by both inhibition of viral replication and blockade of apoptosis in mononuclear, uninfected cells.
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies (Abstract 122) Scottdale , Arizona
L Ruiz , J Romeu , J Martínez-Picado , E Ferrer , E Negredo , C Tural , G Sirera , B Clotet  Structured treatment interruptions in HIV-infected patients on non-nucleoside reverse transcriptase inhibitor-based therapies
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies (Abstract 36) Scottdale , Arizona
J Martinez-Picado , K Morales-Lopetegui , T Wrin , J Garcia Prado , S Frost , C J Petropoulos, B Clotet , L Ruiz  Selection of the M184V mutation during repetitive cycles of structured antiretroviral treatment interruptions.
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies (Abstract 40) Scottdale , Arizona
L Ruiz , J Martinez-Picado , S Marfil , K Morales-Lopetegui , E Ferrer , J Romeu , B Clotet.  Distinct HIV replication outcome after four structured treatment interruptions in chronic HIV- infected patients
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies (Abstract 67) Scottdale , Arizona
J G Padro , T Wrin , J Beauchaine , L Ruiz , C J Petropoulos , B Clotet , R D'Aquila , J Martínez-Picado  Lopinavir resistance of amprenavir-selected, replication-impaired mutants of HIV-1
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies (Abstract 81) Scottdale , Arizona
J Martinez Picado , E Negredo , L Ruiz , C Zala , K Hertogs , C Boucher , R D'Aquila , B Clotet , the SWATCH Study Team  SWATCH study: a multicentre trial of proactive treatment switching. Results at 48 weeks of follow-up
2001	06/04-06/08. 4th International Workshop on HIV drug resistance and treatment strategies. (Abstract 20) Scottdale , Arizona
J A Esté , J Barretina , J Blanco , A Llano , B Clotet  Reduced fitness of HIV-1 that are resistant to CXCR4 antagonists due to alterations in gp120 function.
2001	06/13-06/16. Annual European Congress of Rheumatology (Abstract THU0221) Pague
M Valls-Roc , V Ortiz-Santamaria , A Olivé , M Cervantes , J Gratacós , G Sirera , C Tural , E Negredo , X Tena , B Clotet  Steonecrosis and HIV Infection : Report of eleven cases
2001	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 9) San Diego , USA
J A Esté , E De Clercq  HIV-1 resistance to binding/fusion inhibitors
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract 485) Buenos Aires, Argentina
E Negredo , L Masana , J Ribalta , R Ferrer , J Salazar , L Ruiz , B Clotet  Nuclear Magnetic resonance assessed changes of lipid metabolism in HIV-1 infectet pts with lipodystrophy after switching the Pl by NVP
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract 486) Buenos Aires , Argentina
A Bonjoch , M Torralba , P Montiel , S Pariente , R Paredes , J Carmena , B Clotet  Incidence of lipodystrophy síndrome in 672 HIV-infected patients maintaining the initial HAART
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract 569) Buenos Aires , Argentina
L Ruiz , E Ferrer , E Negredo , J Martínez-Picado , T Puig , C Tural , G Sirera  Stability of HIV-1 RNA in plasma and whole blood specimens for genotypic resistance testing
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract 572) Buenos Aires , Argentina
O Gallego , L Ruiz , A Vallejo , B Clotet , M Leal , V Soriano  Clinical outcome in HIV-infected patients harbouring multinucleoside-resistant genotypes (Q151M, 67/69 Inserts)
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract 632) Buenos Aires, Argentina
J A Esté , J Barretina , J Blanco , A Llano , B Clotet  Longitudinal evaluation of SDF-1 and IL-7 in HIV-1 individuals. Markers of the emergence of HIV-1 syncytium inducing phenotype
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract LB-04) Buenos Aires, Argentina
J Blanco , J Barretina , B Clotet , J A Esté  HIV infected cells kill uninfected CD4 cells by a mechanism involving gp41 dependent deep cell-to-cell contacts in the absence of fusion
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract LB-P10) Buenos Aires, Argentina
M Quiñones-Mateu , M Tadele , M Parera , A Mas , B Clotet , E Domingo , L Menéndez Arias  Role of serine insertions between codons 69 and 70 of HIV-1 reverse transcriptase: enhancing drug resistance while increasing viral fitness?
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract LB-P13) Buenos Aires, Argentina
E Negredo , S Gel , Er Arisa , J Rosales , L Del Rio , S Johnston , B Clotet , A Bonjoch , A Jou , J Romeu  Bone mineral density (BMD)in HIV-infected patients: a prospective comparative trial
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment (Abstract LB-P17) Buenos Aires, Argentina
E Fernández-Cruz , M A Muñoz-Fernández , J Navarro , B Clotet , J Gonzalez-Lahoz , S Moreno , the STIR-2122 team  Randomized control phase II trial evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection having 300 to 700 ceññs/ml CD4 cell counts: data from a recently unblinded study.
2001	07. 1st IAS Conference on HIV Pathogenesis and treatment. (Abstract 397) Buenos Aires , Argentina
M A Martínez , A Ibañez , B Clotet  Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy
2001	07.1st IAS Conference on HIV Pathogenesis and treatment (Abstract 1) Buenos Aires , Argentina
B Clotet  NNRTIs Vs Pls: with what to start therapy
2001	10/28-10/31. 8th European Conference on Clinical Aspects and treatment of HIV infection (Abstract LB/P4) Athens
E Fernandez-Cruz , J Navarro , M A Muñoz-Fernández , B Clotet , J Gonzalez-Lahoz , S Moreno , J M Gatell , J M Peña , J Pérez Molina , D Podzamczer , P López for the STIR-2102 team.  Results from a recently unblended phase II trial (STIR-2120) evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection
2001	10/28-10/31. 8th European Conference on Clinical Aspects and treatment of HIV infection (Abstract P126) Athens
M van der Valk, J J P Kastelein , R L Murphy , F Van Let , C Katlama , A Horban , M Glesby , G Behrens , B Cloete , P Reis on behalf of Atlantic Study Team  Rise in HDL-cholesterol associated with NVP containing antiretroviral therapy in HIV-1 infected patients is sustained ober 48 weeks of treatment.
2001	10/28-10/31. 8th European Conference on Clinical Aspects and treatment of HIV infection (Abstract P235) Athens
B Clotet , S Moreno , J González , J M Miró , J R Arribas , C Barros , L Usán , E Cabrero , R Rode , R Reitmayer , Spain EAP Study Group  Efficacy and safety results of Lopinavir/r based HAART treatment in expanded access program in Spain through W24
2001	10/28-10/31. 8th European Conference on Clinical Aspects and treatment of HIV infection (Abstract P399) Athens
B Clotet , A Hill , M Popescu  Occurrence of HIV protease mutations in patients failing nelfinavir containing HAART. Data from three clinical studies and two observational cohorts.
2001	10/28-10/31.8th European Conference on Clinical Aspects and treatment of HIV infection (Abstract 026) Atenas
C Fagard , A Oxenius , S Yerly , H Gunthard , A Mc Lean , M Le Braz , F García , M Plana , J M Tiercy , E Bernasconi , M Battergay , M Fischer , H J Furrer , P Vernazza , A Telenti , R Philips , B Clotet , T Perneger , L Perrin , B Hirschel  CD4 changes during planned treatment interruptions. The SSITT trial
2001	12/14-12/20. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. (Abstract A-37797)Chicago, USA
C R Fumaz , A Tuldrà , M J Ferrer , E Negredo , S Gel , A Bonjoch , L Ruiz , B Clotet  Impact of Central Nervous System disorders on quality of life and adherence to treatment of HIV+1 patients treated with efavirenz
2001	Clinical Aspects and treatment of HIV infection (Abstract P235 Athens
B Clotet , S Moreno , J González Lahoz , J M Miró , J R Arribas, C Barros , L Usán , E Cabrero , R Rode , R Reitmayer and Spain EAP Study Group  Efficacy and safety results of Lopinavir based HAART treatment in expanded access program in Spain through W24
2000	01/30-02/02. 7th Conference on Retroviruses and Opportunistic Infections (Abstract 206 ) San Francisco
L Ruiz , E Negredo , P Domingo , A Bonjoch , R Paredes , E Francia , M Balagué , J Romeu , A Arnó , C R Fumaz , S Johnston , G Sirera , C Tural , B Clotet   Clinical, virological and innunological benefit of switching the portease inhibitor (PI) by nevirapine (NVP) in HAART experienced patients suffering Lipodystrophy (LD): 36 week follow-up.
2000	04/05-04/07 .V Reunión Nacional sobre el SIDA. Pamplona , Spain
J Blanco , J Barretina , B Clotet , J A Esté   Factores virales independientes del uso de coreceptores junto con la activación del sistema inmune contribuyen a la muerte de células CD8 durante la infección por el virus de la inmunodeficiencia humana.
2000	10.Glasgow.
Autran B., Carcelain G., Samri A., Mollet L., Tubiana R., Ruiz L., Clotet B., Katlama C., Debré P.  T cell responses to HIV and immune-based therapeutic strategies.
2000	17enes Jornades de la Societat Catalana de Biología. Sitges.
Cabana M, Fernández G, Parera M, Clotet B i Martínez MA.   Caracterizació de l´activitat I el fenotip de la protease del virus de la immunodeficència humana tipus-1 (VIH-1) mitjançant un sistema d´escrining genètic basat en el bacteriòfag lambda.
2000	40th. ICAAC. Toronto
Tural C., Ruiz L., Holtzer C., Viciana P., González J., Ferrer E., Martínez-Picado J., Ruiz I., Dalmau D., Domingo P., Been A., Boucher Ch., Shapiro J., Romeu J., Sirera G., Clotet B.  The potential role of resístanse decisión support software with or without expert advice in a trial of HIV genotyping versus standard of care – The havanna trial.
2000	40th. ICAAC. Toronto
Sirera G., Cervantes M., Tural C., Sala M., Romeu J., Grataos E., Negredo E., Bonjoch A., Joua A., Olivé A., Rey-Joly C., Segura F., Clotet B.  Osteonecrosis and HIV infection: report of eleven cases.
2000	40th. ICAAC. Toronto
Wensing AMJ, Holtzer CD., De Groot T., Albert J., Clotet B., Van Lunzen J., Nielsen C., Perrin L., Schneider F., Vandamme A. Boucher CH., Schuurman R.  The prevalence of HIV-1 resistance associated mutations in a large ARV naïve european population. A baseline analysis of the SERVICE project.
2000	40th. ICAAC. Toronto
Fumaz CR., Tuldra A., Ferrer MJ., Negredo E., Gel S., Ruiz L., Martínez-Picado J., Clotet B.  Psichological impact of the trimestral alternation of triple combinations of antiretrovirals in HIV-1+ patients
2000	40th. ICAAC. Toronto
Negredo E., Cruz L., Ruiz L., Bonjoch A., Gel S., Johnston S., Fumaz CR, Tuldrà A., Romeu J., Sirera G., Tural C., Clotet B.   Impact of switching from Portease Inhibitors to Nevirapine or Efavirenz in patients with viral supression.
2000	4nd International Workshop on Drug Resistance and Treatment Strategies. Sitges
Martínez MA, Cabana M, Parera M and Clotet B.   Characterization of the activity and phenotype of different HIV-1 protease variants using a bacteriophage lambda-based genetic screen system.
2000	7th International Discussion Meeting in HIV Dynamics and Evolution. Seattle
Martinez MA, Ibañez A and Clotet B.   Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
2000	7th. Conf. on Retroviruses and Opportunistics Infections. San Francisco
J.Tor, C.Tural, I. Ojanguren, J. Romeu, D. Fuster, C. Rovira, G. Sirera, JA. Jiménez, R. Muga, C. Rey-Joly, B. Clotet.   Histological damage of Hepatitis C virus in HIV infected patients.
2000	7th. Conf. on Retroviruses and Opportunistics Infections. San Francisco.
V. Miller, A. Mocroft, B. Clotet, B. Ledergerber, O Kirk, A. D’Arminio Monforte, JD Lundgren for the EuroSIDA cohort.  Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: The EuroSIDA cohort.
2000	7th. Conf. on Retroviruses and Opportunistics Infections. San Francisco.
L.Ruiz, J. Martínez-Picado, J. Romeu, E. Negredo, A. Tuldrà, C. Tural, B. Clotet.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral supresión.
2000	7th. Keystone Symposium on HIV replication. Keystone
Esté JA., Cabrera C., Gutierrez A., Blanco J., O’Brien W., Clotet B.  Interaction of zinc ions with the HIV-1 coreceptor CXCR4
2000	European Symposium on Lipodystrophy and HIV Infection. Marrakech
Negredo E., Ruiz L., Jiménez O., Coll J., Ojanguren I., Nunes V., Galan A., Rodríguez B., Ariza A., Bonjoch A., Tural C., Clotet B.  Screening blood tests and muscle biopsies to identify mitochondrial toxicity (MT) in patients (pts) suffering lipodystroply (LPD).
2000	European Symposium on Lipodystrophy and HIV Infection. Marrakech
CR Fumaz, A. Tuldra, MJ Ferrer, E Negredo, A Bonjoch, C Tural, L Ruiz, B Clotet.  Impact of Lipodystrophy on quality of life, adherence and emotional status of hiv-positive patients.
2000	Glasgow.
Yust I., Mocroft A., Turner D., Katlama C., Clotet B., Kirk O., Van Lunzen J., Reiss P., Burke M., Chiesi A., Lundgren J., for the EuroSIDA study group.  The effect of HAART on retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe.
2000	V European Conference on experimental AIDS Research. Madrid
Gutierrez A., Llano A., Blanco J., Barretina J., Cabrera C., Clotet B., Esté JA.  Correlation of chemokine SDF-1 levels in plasma of HIV-1 positive individuals and emergence of the syncytium inducing phenotype.
2000	V European Conference on experimental AIDS Research. Madrid
Blanco J., Barretina J., Clotet B., Esté JA.  Analyzing the steps of HIV-1 envelope-induced apoptosis
2000	V Reunión Nacional sobre el SIDA. Pamplona
Gutierrez A., Cabrera C., Blanco J., Barretina J., Litovchick A., Lapidot A., Evdokimov AG, Clotet B., Esté JA.  Inhibición de la replicación del VIH-1 por aminoglicosidos con L-argininas en las primeras etapas de la infección.
2000	V Reunión Nacional sobre el SIDA. Pamplona
Tuldrà A., Fumaz CR., Ferrer MJ., Romeu J., Paredes R., Ruiz L., Clotet B  Impacto psicológico de las interrupciones intermitentes de tratamiento en pacientes con carga viral no detectable.
2000	V Reunión Nacional sobre el SIDA. Pamplona
Tuldrà A., Fumaz CR., Ferrer MJ., Bayés R., Bonjoch A., Cruz L., Jou A., Negredo E., Romeu J., Sirera G., Tural C., Clotet B.  Motivos de pérdida de dosis en pacientes en HAART con alta y baja adhesión. Influencia del tiempo de tratamiento.
2000	XIII International AIDS Conference. Durban.
Llano C., Blanco J., Barretina J., cabrera C., Gutierrez A., Clotet B., Esté JA.  Lower levels of stromal cell-derived factor 1 (SDF-1) are associated with the emergence of more pathogenic strains of HIV-1.
2000	XIII International AIDS Conference. Durban.
Esté JA., Cabrera C., Gutierrez A., Blanco J., Barretina J., Clotet B.  Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
2000	XIII International AIDS Conference. Durban.
Cabrera C., Blanco J., Gutierrez A., Clotet B., Esté JA.  Entry of X4 or R5 HIV-1 strains does not correlate with the level of expression or the functionality of CXCR4 or CCR5 chemokine receptors in PBMC.
2000	XIII International AIDS Conference. Durban.
Tuldrà A., Fumaz CR., Ferrer MJ., Romeu J., Ruiz L., Clotet B.  Psychological Impact of intermittent treatment interruptions in patients with non-detectable HIV-1 viral load.
2000	XIII International AIDS Conference. Durban.
J. Blanco, J. Barretina, A. Gutierrez, C. Cabrera, B. Clotet and JA Esté.  The binding of HIV particles to primary T cells is modulated by CD4-dependwent and CD4-independent interactions and preferentially targets memory CD4T cells.
2000	XIII International AIDS Conference. Durban.
MA Martínez, F. Puig, M. Cabana, M. Guilera, M. Jiménez-Barcons, G. Sirera, C. Tural, B. Clotet, JM Sánchez-Tapias, J. Rodes, JC Saiz.  Prevalence and route of transmisión of infection with a novel DNA virus (TT virus), hepatitis C virus, and hepatitis G virus in patients infected with human immunodeficiency virus.
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 125) Chicago, USA
M Gómez Cano , A Rubio , T Puig , M Pérez Olmeda , L Ruiz , M Leal , B Clotet , V Soriano  Prevalence of drug resistance mutations over time in naive HIV+ subjects living in Spain
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 18) Chicago, USA
C Katlama , R Murphy , V Johnson , K Squires , A Horban , J Gatell , B Clotet , S Staszewski , R Van Leeuwen , N Clumeck , M Moroni , A Pavia , Sommadossi , J Lange  The Atlantic Study : A Randomised Open-Label Study comparing 2 PI- containing regimen
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 191) Chicago, USA
J Tor , C Tural , I Oranguren , J Romeu , Z Villaseca , C Rovira , A Veny , G Sirera , J A Jimenez , R Muga , B Clotet , C Rey-Joly  Histological damage of hepatitis C virus in HIV infected patients. A case control study
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 378) Chicago, USA
P Vernazza , C Katlama , B Clotet , A Plettenberg , L Goh , A Cutrell , S Purdon   Intensification of stable background antiretroviral therapy with Ziageen
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 455)Chicago , USA
C Tural , G Sirera , J Romeu , A Bonjoch , A Jou , D Andreu , L Ruiz , A Arnó , R Paredes , B Clotet  A 24 Month follow-up of cytomegalovirus retinitis without secondary prophylaxis following highly active antiretroviral therapy
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract 652) Chicago, USA
J Romeu , A Bonjoch , A Arnó , M Balagué , S Gel , B Garces , S Johnston , B Clotet  Lipodystrophy index by anthropometric parameters (LIAP). An approach to the diagnosis of lipodystrophy by measurable parameters in patients taking protease inhibitors
1999	01/31-02/04. 6th Conference on Retrovirus and Opportunistic Infections (Abstract LB14) Chicago, USA
L Ruiz , A Bonjoch , R Paredes , S Johnston , A Arnó , J Romeu , M Balagué , G Sirera , A Tuldrà , C R Fumaz , B Clotet , LP Study Group "irsicaixa foundation"  A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the Protease Inhibitor (PI) by Nevirapine (NPV) in HAART-experienced patients suffering Lipodystrophy (LD)
1999	03/21-03/26. 12th International Conference on Antiviral Research. Jerusalem , Israel
J A Esté , C Cabrera , A Gutierrez , J Blanco , D Schols , B Clotet , G Henson , G Bridger , E de Clercq  Blockade of CXCR4 prevents the emergence of X4 , T-cell tropic , syncytium-inducing strains of HIV-1
1999	03/26-03/27. The Third European Stavudine Symposium. Cannes, France
L Ruiz , A Bonjoch , R Paredes , S Johnston , A Arnó , J Romeu , M Balagué , G Sirera , A Tuldrà , C R Fumaz , B Clotet , LP Study Group irsicaixa foundation  A multi-center, randomized , open-label , comparative trial of the clinical benefit of switching the Protease Inhibitor (PI) by Nevirapine (NPV) in HAART-experienced patients suffering lipodystrophy (LD)
1999	04/13-04/16. 5º Congreso Nacional sobre el SIDA ( Abstract CP8-6)Santiago de Compostela , Spain
A Bonjoch , J Macías , E Martínez , A Poza , R Paredes , M Leal , J Gatell , J González-Lahoz , M Balagué , B Clotet  Estudio multicéntrico comparativo de terapia antiretroviral combinada con o sin nevirapina
1999	04/13-04/16. 5º Congreso Nacional sobre el SIDA (Abstract CP1-5) Santiago de Compostela , Spain
A Tuldrá , M J Ferrer , C R Fumaz , R Bayes , J Romeu , G Sirera , C Tural , A Bonjoch , A Jou , R Paredes , B Clotet  Mejora de la adhesión al tratamiento HAART y de la supresión de la replicación viral tras la aplicación de un programa de asesoramiento psicoeducativo
1999	04/13-04/16. 5º Congreso Nacional sobre el SIDA. Santiago de Compostela , Spain
A Gutierrez , C Cabrera , J Blanco , B Clotet , J A Esté  Interacción de iones Zn2+ con el receptor de cepas T-tropicas de VIH, CXCR4
1999	04/13-04/16. 5º Congreso Nacional sobre el SIDA. Santiago de Compostela , Spain
M Pérez Olmeda , A Rubio , T Puig , G Cano , L Ruiz , M Leal , B Clotet , V Soriano  Reciclaje de fármacos antiretrovirales según el patron de resistencias genotípicas
1999	04/13-04/16. 5º Congreso Nacional sobre el SIDA. Santiago de Compostela, Spain
C Cabrera , A Gutierrez , B Clotet , J A Esté  Revisión del fenotipo X4 a R5 del VIH por antagonismo al receptor CXCR4
1999	05/15-05/16. 6è Congrès Català de Medicina Interna. Sitges , Spain
A Tuldrà , C R Fumaz , R Paredes , M J Ferrer , R Bayés , E Negredo , B Clotet  Experiencia amb ritonavir en solució oral: acceptabilitat , tolerabilitat i adhesió
1999	05/15-05/16. 6è Congrès Català de Medicina Interna. Sitges, Spain
A Ibañez , B Clotet , M A Martínez  Cuantificación del DNA del VIH-1 total e integrado en pacientes sometidos a potente terapia antiretroviral. Evolución del DNA integrado durante el periodo de supresión de la viremia plasmática.
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 114) San Diego , USA
J L Casado , K Hertogs , L Ruiz , A Van Cauwenberge , F Dronda , A Arnó , S Bloor , J Blazquez , B Clotet , B Larder  Rate of non-nucleoside reverse transcriptase inhibitor resistance amomg patients failing a nevirapine plus protease inhibitor-containing regimen
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 126) San Diego , USA
M P de Pasquale , E Rosenberg , A Quayle , C Temblay , J Martínez-Picado , J Allega , L Sutton , L Shi , A V Savara , S Boswell , P Sax , M Hirsch , A Caliendo , D Anderson , B D Walker , R T D'Aquila  Primary HIV infection: in vivo fitness of pre-therapy resistant mutants and potential for secondary spread of HIV from semen
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 148) San Diego , USA
K Van Vaerenbergh , K Van Laethem , J Albert , C Boucher , B Clotet , M Floridia , J Gerstoft , C Nielsen , L Perrin , M F Pirillo , L Ruiz , J C Schmit , F Schneider , A Schoolmeester , R Schuurman , H J Stellbrink , L Stuyver , J Van Lunzen , E Van Wijngaerden, S Vella , S Yerly , E De Clerq , J Desmyster , A M Vandamme  Prevalence of the multidrug resistant 6 bp insert at RT codon 69 among European HIV-1 infected patients receiving various combinations of nucleoside analogues
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 168) San Diego , USA
L Ruiz , S Marfil , M A Martínez , J Martínez-Picado , A Arnó , A García , A Jou , B Clotet  Effect of Interleukin-2 low doses on HIV-1 total and integrated DNA in advanced HIV infection
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 53) San Diego , USA
M Pérez-Olmeda , A Rubio , L Ruiz , J del Romero , C Briones , M Gómez-Cano , M Leal , B Clotet , C Rodríguez , V Soriano  Incidence of drug resistance genotypes in naive HIV-infected subjects in Spain (1993-1998)
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 72) San Diego , USA
J Martínez-Picado , M D Pascuale , L Ruiz , V Miller , A V Savara , L Sutton , B Clotet , R T D'Aquila  Clonal sequencing compared to population sequencing for detection of resistance mutations and their linkage
1999	06/23-06/26. 3rd International Workshop on HIV drug resistance and treatment strategies (Abstract 99) San Diego , USA
M A Martínez , M Cabana , M Parera , B Clotet , A Gutierrez , J A Esté  A bacteriophage lambda-based genetic screen for the characterization of the activity of HIV-1 protease and for the evaluation of protease inhibitors
1999	06/26-06/28. 1st International Workshop on Adverse drug reactions and Lipodystrophy in HIV (Abstract 31) San Diego , USA
L Ruiz , E Negredo , A Bonjoch , R Paredes , J Romeu , G Sirera , R C Fumaz , L Zamora , B Clotet , LD Study Group  A Multicentre , randomized , open-label, comparative trial of the clinical immunological and virological benefit of switching the PI by nevirapine in HAART-experienced patients suffering lipodystrophy
1999	06/26-06/28. 1st International Workshop on Adverse drug reactions and Lipodystrophy in HIV (Abstract 57) San Diego, USA
C R Fumaz , A Tuldrá , M J Ferrer , R Paredes , B Clotet  Impact of PI-sparing HAART regimens on adherence, quality of life and emotional status of HIV-positive patients suffering lipodystrophy
1999	09/25-09/29. 39th ICCAC (Abstract 1977)
A Bonjoch , J Macias , E Martinez , A Poza , R Paredes , M Leal , J Gatell , J González-Lahoz , E Negredo , B Clotet  Multicentre open label 2-arm cohort-study comparing a 4-drug nevirapine-containing antiviral therapy versus a 3-drug combination without nevirapine
1999	09/25-09/29. ICAAC (Abstract 1170)
J Rockstroh , B Clotet , C katlama , S Purdon , A Cutrell , C Stone , M Aitkhaled  The role of Abacavir (ABC, 1592) in Antiretroviral therapy-experienced patients: preliminary 48 week results from a randomized double-blind trial
1999	09/25-09/29. ICAAC (Abstract 1293)
J Romeu , G Sirera , M J Rego , E Negredo , A Bonjoch , A Jou , L Cruz , B Clotet  Cumulative risk for developing hyperlipidemia in HIV infected patients treated with protease inhibitors
1999	09/25-09/29. ICAAC (Abstract 595)
A Tuldrà , C R Fumaz , M José Ferrer , R Bayés , A Arnó , M Balagué , R Paredes , L Ruiz , J Romeu , G Sirera , C Tural , D Burguer , B Clotet  An specific intervention improves long term adherence to HAART and ensuing virological outcome
1999	10/23-10/27. 7th European Conference on Clinical Aspects
F García , M M Alonso , J Romeu , H Knobel , J Arrizabalaga , D Podzamczer , D Dalmau , L Ruiz , F Vidal , A Frances , F Segura , J L Gómez-Sirvent , A Cruceta , B Clotet , T Pumarola , T Gallart , J M Miró , J M Gatell , Spanish EARTH-2 study  An open randomized trial of indinavir , lamicudine and stavudine versus stavudine/zidovudine and lamivudine in HIV-1 infected patients with a CD$+T cell acount above 500/mm3
1999	10/23-10/27. 7th European Conference on Clinical Aspects and Ttm HIV Infection (Abstract 841) Lisboa , Portugal
R Paredes , A Mocroft , O Kirk , S E Barton , J Van Lunzen , T L Katzenstein , F Antunes , J D Lundgren , B Clotet, Eurosida Study Group  Predictors of virological success and ensuing failure among HIV+patients starting Book of Abstracts
1999	10/23-10/27. 7th European Conference on Clinical Aspects and Ttm HIV Infection (Abstract n 207)Lisboa , Portugal
B Clotet , A Plettenbbeg , C Katlama , S Purdon , A Cutrell , A M Ait-Khaled , C Stone for the CNA3002 European Study Team  Intensification of stable background therapy with Abacavir: preliminary 48 week data
1999	10/23-10/27. 7th European Conference on Clinical Aspects and Ttm. HIV Infection (Abstract 792) Lisboa , Portugal
J Romeu , C Tural , G Sirera , M J Rego , E Negredo , A Bonjoch , A Jou , L Cruz , B Clotet  Long-term risk for developing protease inhibitor-associated (PI-A) fat redistribution (FR)
1999	10/23-10/27. 7th European Conference On Clinical Aspects and Ttmt HIV Infection . Lisboa , Portugal
V Miller , F Houyer , N Clumeck , S Staszewky , A M Vandamme , J Lundgren , M Youle , J Lange , RGI European Expert Panel , D Clotet as a participating member  Guidelines for the use of HIV grug resistance testing in clinical management: a European Perspective
1999	10/23-10/27. 7th European Conference on Clinical aspects and Ttn HIV Infection (Abstract 105) Lisboa , Portugal
L Ruiz , A Pérez-Olmeda , A Rubio , T Puig , C Briones , R De la Rosa , M Gómez-Cano , L Stuyver , C Alvarez , L Zamora , M Leal , V Soriano , B Clotet , ERASE-2 Study Group  Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain : a multicenter cross-sectorial study (ERASE-2)
1999	10/23-10/27. 7th European Conference On Clinical Aspects ant Ttm HIV Infection
O Kirk , A Mocroft , J N Bruun , R Hemmer , B Clotet , V Miller , J P Viard , A N Philips , J D Lungren  A comparison of Virological , immunological and clinical response in patients starting RTV , SQV or IDV. Results from the EuroSIDA Study
1999	10/23-10/27.7th European Conf On Clinical Aspects and Ttm HIV Infection (Abstract 512)Lisboa, Portugal
A Tuldrà , C R Fumaz , M J Ferrer , R Bayés , A Arnó , E Negredo , R Paredes , L Ruiz ,J Romeu , G Sirera , C Tural , D M Burguer , B Clotet  Predicting long-term adherence to HAART
1999	10/27-10/28. VI Congreso Nacional de Virología (Abstract C07-3) Madrid, Spain
M Cabana , B Clotet , M A Martínez  Aparición y evolución genética de variantes de VIH con mutaciones que confieren resistencia a múltiples inhibidores de la transcriptasa inversa y la proteasa
1999	11/19. II International Workshop on HIV Erradication. II Simposium Fundació IrsiCaixa. Badalona , Spain
L Ruiz  Interruption of antiretroviral treatment in patients with CD4/CD8>1
1999	11/19. II International Workshop on HIV Erradicatrion. II Simposium Fundació IrsiCaixa. Badalona, Spain
J A Esté  Role of CXCR4 in HIV-induced pathogenesis
1999	1999. 6th International Symposium on Hepatitis C and related viruses. Bethesda , USA
M Jiménez-Barcons , A Ibáñez , C Menéndez , A Sánchez-Pueyo , B Clotet , M A Martínez , J M Sánchez-Tapias , J Rodés , J C Saiz  Mechanism involved in hepatits G virus evolution
1999	Congreso Nacional de Virología (Abstract P4-05) Madrid, Spain
J Barretina , J Blanco , L L Madr , C Altisent , T Español , I Caragol , B Clotet , J A Esté  Evaluación del posible papel de las C-C quimiocinas como factores protectores de la infección por el virus de la Inmunodeficiencia Humana Tipo 1 (VIH-1) en pacientes hemofílicos seronegativos expuestos a hemoderivados contaminados
1999	Congreso Nacional de Virología (Abstract